Details of the Drug Combinations

General Information of This Drug (ID: DMDI269)

Drug Name
Docetaxel   DMDI269
Synonyms
EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Breast carcinoma N.A. Approved [1]
Head and neck cancer 2D42 Approved [1]
Leiomyosarcoma 2B58 Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Prostate adenocarcinoma N.A. Approved [1]
Prostate cancer 2C82.0 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Urinary system neoplasm N.A. Approved [1]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1124 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
(-)-englerin A + Docetaxel DCRF1J5 (-)-englerin A Ewing sarcoma (Cell Line: TC-71) [3]
ABIRATERONE + Docetaxel DCC7WBE ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
ABIRATERONE + Docetaxel DCW9IYN ABIRATERONE Anaplastic large cell lymphoma (Cell Line: SR) [3]
ABIRATERONE + Docetaxel DCV7FWX ABIRATERONE Astrocytoma (Cell Line: U251) [3]
ABIRATERONE + Docetaxel DCGBDDG ABIRATERONE Astrocytoma (Cell Line: SNB-19) [3]
ABIRATERONE + Docetaxel DC1BVQS ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [3]
ABIRATERONE + Docetaxel DCKSE8K ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
ABIRATERONE + Docetaxel DC3LDCZ ABIRATERONE Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
ABIRATERONE + Docetaxel DC80HQ5 ABIRATERONE Glioma (Cell Line: SF-539) [3]
ABIRATERONE + Docetaxel DCPTGNZ ABIRATERONE Plasma cell myeloma (Cell Line: RPMI-8226) [3]
ABIRATERONE + Docetaxel DCKQI2A ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
ABIRATERONE + Docetaxel DCMCZAW ABIRATERONE Carcinoma (Cell Line: RXF 393) [4]
ABIRATERONE + Docetaxel DCNH026 ABIRATERONE Carcinoma (Cell Line: MCF7) [4]
ABIRATERONE + Docetaxel DC22X7O ABIRATERONE Invasive ductal carcinoma (Cell Line: T-47D) [4]
ABIRATERONE + Docetaxel DC3RUFP ABIRATERONE Adenocarcinoma (Cell Line: OVCAR3) [5]
ABIRATERONE + Docetaxel DCKAXAL ABIRATERONE Adenocarcinoma (Cell Line: NCIH23) [5]
ABIRATERONE + Docetaxel DC3VEMX ABIRATERONE Adenocarcinoma (Cell Line: A549) [5]
ABIRATERONE + Docetaxel DCPXSN8 ABIRATERONE Adenocarcinoma (Cell Line: SW-620) [5]
ABIRATERONE + Docetaxel DCFUFSX ABIRATERONE Adenocarcinoma (Cell Line: HCT-15) [5]
ABIRATERONE + Docetaxel DCW6KLK ABIRATERONE Adenocarcinoma (Cell Line: HCC-2998) [5]
ABIRATERONE + Docetaxel DCH06JM ABIRATERONE Adenocarcinoma (Cell Line: HT29) [5]
ABIRATERONE + Docetaxel DCWZBYF ABIRATERONE Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
ABIRATERONE + Docetaxel DCUGHZN ABIRATERONE Amelanotic melanoma (Cell Line: M14) [5]
ABIRATERONE + Docetaxel DC3XDCQ ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
ABIRATERONE + Docetaxel DCI4FQO ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
ABIRATERONE + Docetaxel DCS8KXH ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
ABIRATERONE + Docetaxel DC2831Z ABIRATERONE Large cell lung carcinoma (Cell Line: NCI-H460) [5]
ABIRATERONE + Docetaxel DCW5S8S ABIRATERONE Lung adenocarcinoma (Cell Line: NCI-H522) [5]
ABIRATERONE + Docetaxel DCI6EOA ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [5]
ABIRATERONE + Docetaxel DCI1A9J ABIRATERONE Melanoma (Cell Line: UACC-257) [5]
ABT-263 + Docetaxel DCYVER0 ABT-263 Ewing sarcoma (Cell Line: TC-71) [5]
Acamprosate + Docetaxel DCBRHYT Acamprosate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Aciclovir + Docetaxel DCGBHWJ Aciclovir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Albendazole + Docetaxel DC7010B Albendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Aminosalicylic acid + Docetaxel DCAJCJ2 Aminosalicylic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Amodiaquine + Docetaxel DC79OPO Amodiaquine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Anastrozole + Docetaxel DCORFDL Anastrozole Adenocarcinoma (Cell Line: HCT-15) [3]
Anastrozole + Docetaxel DCG507U Anastrozole Adenocarcinoma (Cell Line: HT29) [3]
Anastrozole + Docetaxel DCC1U6M Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Anastrozole + Docetaxel DCHMNE9 Anastrozole Malignant melanoma (Cell Line: UACC62) [3]
Anastrozole + Docetaxel DCWX9IM Anastrozole Melanoma (Cell Line: MALME-3M) [3]
Anastrozole + Docetaxel DC77QMP Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Arfolitixorin + Docetaxel DCAWOQO Arfolitixorin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Armodafinil + Docetaxel DCGZ59U Armodafinil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Artemisinin + Docetaxel DC204W2 Artemisinin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Artemisinin + Docetaxel DCMNR9G Artemisinin DD2 (Cell Line: DD2) [3]
Artemisinin + Docetaxel DCO6SVE Artemisinin Hepatoblastoma (Cell Line: HB3) [3]
AS-1949490 + Docetaxel DCVK66O AS-1949490 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Atenolol + Docetaxel DC12MNJ Atenolol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Azatadine + Docetaxel DC3CJUV Azatadine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
AZD8055 + Docetaxel DCCPZWL AZD8055 Ewing sarcoma (Cell Line: TC-71) [3]
BHV-0223 + Docetaxel DCJ4GHV BHV-0223 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Bifemelane + Docetaxel DCCWVBF Bifemelane DD2 (Cell Line: DD2) [3]
BIO-300 + Docetaxel DCUD45U BIO-300 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
BIO-300 + Docetaxel DCKA2C3 BIO-300 Malignant melanoma (Cell Line: UACC62) [5]
BIO-300 + Docetaxel DC0CIWW BIO-300 Melanoma (Cell Line: MALME-3M) [5]
BRL-15572 + Docetaxel DCG8A4X BRL-15572 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Bumetanide + Docetaxel DCE4OQB Bumetanide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Cabazitaxel + Docetaxel DCJDSYU Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [3]
Cabazitaxel + Docetaxel DCZIZDJ Cabazitaxel Adenocarcinoma (Cell Line: OVCAR3) [3]
Cabazitaxel + Docetaxel DCQXF0G Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [3]
Cabazitaxel + Docetaxel DCA23MJ Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [3]
Cabazitaxel + Docetaxel DC5WZCS Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Cabazitaxel + Docetaxel DC0WZ2D Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Cabazitaxel + Docetaxel DC9DP82 Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Cabazitaxel + Docetaxel DC87ETI Cabazitaxel Astrocytoma (Cell Line: U251) [3]
Cabazitaxel + Docetaxel DCIR09L Cabazitaxel Astrocytoma (Cell Line: SNB-19) [3]
Cabazitaxel + Docetaxel DCDEMGQ Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [3]
Cabazitaxel + Docetaxel DCHVO1P Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Cabazitaxel + Docetaxel DC5GN0I Cabazitaxel Glioma (Cell Line: SF-295) [3]
Cabazitaxel + Docetaxel DCACUDZ Cabazitaxel Glioma (Cell Line: SF-268) [3]
Cabazitaxel + Docetaxel DCHB6J6 Cabazitaxel Glioma (Cell Line: SF-539) [3]
Cabazitaxel + Docetaxel DCE3EJZ Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Cabazitaxel + Docetaxel DCJAM65 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Cabazitaxel + Docetaxel DCVKQNG Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Cabazitaxel + Docetaxel DC2BLMT Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [3]
Cabazitaxel + Docetaxel DC7XYES Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [3]
Cabazitaxel + Docetaxel DC1P6X8 Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Cabazitaxel + Docetaxel DCK61IS Cabazitaxel Malignant melanoma (Cell Line: UACC62) [3]
Cabazitaxel + Docetaxel DCPD55X Cabazitaxel Melanoma (Cell Line: UACC-257) [3]
Cabazitaxel + Docetaxel DCUYWDR Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Cabazitaxel + Docetaxel DCPPG61 Cabazitaxel Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Cabazitaxel + Docetaxel DC7M91U Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [3]
Cabazitaxel + Docetaxel DCMD64H Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [3]
Cabazitaxel + Docetaxel DCZQUB4 Cabazitaxel Carcinoma (Cell Line: RXF 393) [4]
Cabazitaxel + Docetaxel DCQBZD2 Cabazitaxel Colon adenocarcinoma (Cell Line: COLO 205) [4]
Cabazitaxel + Docetaxel DCQIW03 Cabazitaxel Invasive ductal carcinoma (Cell Line: T-47D) [4]
Cabazitaxel + Docetaxel DC0L0N5 Cabazitaxel Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Cevimeline + Docetaxel DCBJN2I Cevimeline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Chloroquine + Docetaxel DCI62LE Chloroquine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Cinacalcet + Docetaxel DC1JVA0 Cinacalcet Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Ciprofibrate + Docetaxel DC7PMIN Ciprofibrate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Citalopram + Docetaxel DC7M25U Citalopram Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Clopidogrel + Docetaxel DC9BXF4 Clopidogrel Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Crizotinib + Docetaxel DCP94OL Crizotinib Adenocarcinoma (Cell Line: NCIH23) [3]
Crizotinib + Docetaxel DCRNS9U Crizotinib Adenocarcinoma (Cell Line: A549) [3]
Crizotinib + Docetaxel DCE8M2E Crizotinib Adenocarcinoma (Cell Line: HCC-2998) [3]
Crizotinib + Docetaxel DCQBU14 Crizotinib Adenocarcinoma (Cell Line: HCT116) [3]
Crizotinib + Docetaxel DCT21SD Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Crizotinib + Docetaxel DCWV777 Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Crizotinib + Docetaxel DCF7ID4 Crizotinib Astrocytoma (Cell Line: SNB-19) [3]
Crizotinib + Docetaxel DCIQ2GK Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Crizotinib + Docetaxel DCUKMNT Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Crizotinib + Docetaxel DCFFGBO Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Crizotinib + Docetaxel DCEJ0U4 Crizotinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Crizotinib + Docetaxel DCRDRG4 Crizotinib Prostate carcinoma (Cell Line: PC-3) [3]
Crizotinib + Docetaxel DC4SAXT Crizotinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Dacarbazine + Docetaxel DC8TOX8 Dacarbazine Adenocarcinoma (Cell Line: HT29) [3]
Dacarbazine + Docetaxel DCHE0CS Dacarbazine Amelanotic melanoma (Cell Line: M14) [3]
Dacarbazine + Docetaxel DCF3G10 Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Dacarbazine + Docetaxel DC920PD Dacarbazine Melanoma (Cell Line: MALME-3M) [3]
Dacarbazine + Docetaxel DCFXW50 Dacarbazine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Dacarbazine + Docetaxel DCL5XK7 Dacarbazine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Dactinomycin + Docetaxel DCKDMM7 Dactinomycin Carcinoma (Cell Line: MCF7) [4]
Dactinomycin + Docetaxel DCRKSIR Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Dactinomycin + Docetaxel DCYM82H Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [5]
Dactinomycin + Docetaxel DC9NO07 Dactinomycin Adenocarcinoma (Cell Line: A549) [5]
Dactinomycin + Docetaxel DC3HT7O Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dactinomycin + Docetaxel DC7G4XV Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dactinomycin + Docetaxel DCWUGRK Dactinomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Dactinomycin + Docetaxel DCBOKW8 Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Dactinomycin + Docetaxel DC6V2ZT Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [5]
Dactinomycin + Docetaxel DCYJJHH Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Dactinomycin + Docetaxel DC5MI3V Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Dactinomycin + Docetaxel DCWIVTG Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Dactinomycin + Docetaxel DCRM3MR Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Dactinomycin + Docetaxel DC3J1DE Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Dactinomycin + Docetaxel DCH2Y6S Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [5]
Dactinomycin + Docetaxel DC2IPJ6 Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Dactinomycin + Docetaxel DCTGOSZ Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Dactinomycin + Docetaxel DCPZOWZ Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [5]
Desoxycorticosterone pivalate + Docetaxel DCPH3KU Desoxycorticosterone pivalate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Dexmedetomidine + Docetaxel DCATO2P Dexmedetomidine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Dexrazoxane + Docetaxel DCVYDJP Dexrazoxane Melanoma (Cell Line: MALME-3M) [5]
Dextromethorphan + Docetaxel DCJDP3D Dextromethorphan Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
DFN-15 + Docetaxel DCHG5GF DFN-15 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
DFN-15 + Docetaxel DC0B46S DFN-15 Anaplastic large cell lymphoma (Cell Line: SR) [3]
DFN-15 + Docetaxel DCKU2OM DFN-15 Astrocytoma (Cell Line: U251) [3]
DFN-15 + Docetaxel DCI2C1X DFN-15 Astrocytoma (Cell Line: SNB-19) [3]
DFN-15 + Docetaxel DCEK7JE DFN-15 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
DFN-15 + Docetaxel DC3PVRA DFN-15 Chronic myelogenous leukemia (Cell Line: K-562) [3]
DFN-15 + Docetaxel DC3MEE4 DFN-15 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
DFN-15 + Docetaxel DCNQWMS DFN-15 Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
DFN-15 + Docetaxel DC4OR4C DFN-15 Clear cell renal cell carcinoma (Cell Line: A498) [3]
DFN-15 + Docetaxel DCOZMEC DFN-15 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
DFN-15 + Docetaxel DCDEIWJ DFN-15 Glioblastoma (Cell Line: SNB-75) [3]
DFN-15 + Docetaxel DC5WTD9 DFN-15 Glioma (Cell Line: SF-295) [3]
DFN-15 + Docetaxel DCAWGAO DFN-15 Glioma (Cell Line: SF-539) [3]
DFN-15 + Docetaxel DCJT5N2 DFN-15 Glioma (Cell Line: SF-268) [3]
DFN-15 + Docetaxel DCI5O5A DFN-15 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
DFN-15 + Docetaxel DC9WORA DFN-15 Renal cell carcinoma (Cell Line: SN12C) [3]
DFN-15 + Docetaxel DCBIHXB DFN-15 Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
DFN-15 + Docetaxel DC2DQZS DFN-15 Carcinoma (Cell Line: RXF 393) [4]
DFN-15 + Docetaxel DCKMOCR DFN-15 Colon adenocarcinoma (Cell Line: COLO 205) [4]
DFN-15 + Docetaxel DCWDHTD DFN-15 Colon carcinoma (Cell Line: KM12) [4]
DFN-15 + Docetaxel DC1K44G DFN-15 Invasive ductal carcinoma (Cell Line: BT-549) [4]
DFN-15 + Docetaxel DCX4Y41 DFN-15 Invasive ductal carcinoma (Cell Line: T-47D) [4]
DFN-15 + Docetaxel DC97INV DFN-15 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
DFN-15 + Docetaxel DC9E9TK DFN-15 Adenocarcinoma (Cell Line: DU-145) [5]
DFN-15 + Docetaxel DC9F9ZG DFN-15 Adenocarcinoma (Cell Line: OVCAR3) [5]
DFN-15 + Docetaxel DCHYZ4B DFN-15 Adenocarcinoma (Cell Line: A549) [5]
DFN-15 + Docetaxel DCSDAH1 DFN-15 Adenocarcinoma (Cell Line: NCIH23) [5]
DFN-15 + Docetaxel DCMPLMG DFN-15 Adenocarcinoma (Cell Line: HT29) [5]
DFN-15 + Docetaxel DC1UU39 DFN-15 Adenocarcinoma (Cell Line: HCC-2998) [5]
DFN-15 + Docetaxel DCIAJTB DFN-15 Adenocarcinoma (Cell Line: HCT116) [5]
DFN-15 + Docetaxel DCSREZV DFN-15 Adenocarcinoma (Cell Line: SW-620) [5]
DFN-15 + Docetaxel DCO902R DFN-15 Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
DFN-15 + Docetaxel DC6JMK0 DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
DFN-15 + Docetaxel DCSGYIJ DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
DFN-15 + Docetaxel DCIDDO0 DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
DFN-15 + Docetaxel DC4RNAP DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
DFN-15 + Docetaxel DCJ93D8 DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
DFN-15 + Docetaxel DC399XB DFN-15 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
DFN-15 + Docetaxel DCYL7DC DFN-15 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
DFN-15 + Docetaxel DC7E54J DFN-15 Lung adenocarcinoma (Cell Line: NCI-H522) [5]
DFN-15 + Docetaxel DC6JFHL DFN-15 Malignant melanoma (Cell Line: UACC62) [5]
DFN-15 + Docetaxel DC66KPL DFN-15 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
DFN-15 + Docetaxel DCN2W9Q DFN-15 Prostate carcinoma (Cell Line: PC-3) [5]
Dichlorphenamide + Docetaxel DC2EBNC Dichlorphenamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Diethylcarbamazine + Docetaxel DC7FEU3 Diethylcarbamazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Digitoxin + Docetaxel DCV6E2K Digitoxin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Dihydroergotamine + Docetaxel DCV3HEV Dihydroergotamine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Diphenidol + Docetaxel DCUASAK Diphenidol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Ribavirin-TP DCNM6UH Ribavirin-TP Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Sertraline DC9VDUW Sertraline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Pentostatin DCUSRS1 Pentostatin Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + Mebutamate DCHWXR8 Mebutamate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Triiodothyronine DCPUKBZ Triiodothyronine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Diethylcarbamazine DCOBUM5 Diethylcarbamazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + OZ277 DCKQD8K OZ277 DD2 (Cell Line: DD2) [3]
Docetaxel + OZ277 DC24WT2 OZ277 Hepatoblastoma (Cell Line: HB3) [3]
Docetaxel + Ruxolitinib DCEKTQD Ruxolitinib T-cell leukemia/lymphoma (Cell Line: ED-40515) [3]
Docetaxel + Lumefantrine DCZB7S7 Lumefantrine DD2 (Cell Line: DD2) [3]
Docetaxel + Lumefantrine DCIJEGD Lumefantrine Hepatoblastoma (Cell Line: HB3) [3]
Docetaxel + Citalopram DCY0WF5 Citalopram Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + LY335979 DCCRNZ2 LY335979 Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11) [3]
Docetaxel + Ixabepilone DCZ252C Ixabepilone Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Ixabepilone DC1IBG9 Ixabepilone Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Docetaxel + Ixabepilone DCRV3W5 Ixabepilone Glioma (Cell Line: SF-268) [3]
Docetaxel + Ixabepilone DCCKBY9 Ixabepilone High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Ixabepilone DCM968D Ixabepilone Lung adenocarcinoma (Cell Line: HOP-62) [3]
Docetaxel + Ixabepilone DC3CPW0 Ixabepilone Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + Crotamiton DCCMS8H Crotamiton Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Dactinomycin DCXP389 Dactinomycin Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Dactinomycin DCYSCNY Dactinomycin Adenocarcinoma (Cell Line: SW-620) [3]
Docetaxel + Dactinomycin DCFLOGY Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Lapatinib DC4VBJV Lapatinib Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Lapatinib DCHM8YK Lapatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Docetaxel + Lapatinib DCQFXNS Lapatinib Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + Lapatinib DC0OOEX Lapatinib Adenocarcinoma (Cell Line: A549) [3]
Docetaxel + Lapatinib DCQ82XX Lapatinib Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Lapatinib DCU75ES Lapatinib Adenocarcinoma (Cell Line: SW-620) [3]
Docetaxel + Lapatinib DCVZJK5 Lapatinib Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + Lapatinib DCJYPDC Lapatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Docetaxel + Lapatinib DCJ2DRU Lapatinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Lapatinib DCG0H0W Lapatinib Astrocytoma (Cell Line: U251) [3]
Docetaxel + Lapatinib DC3SG1L Lapatinib Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Lapatinib DCD71JE Lapatinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Docetaxel + Lapatinib DCIDU6D Lapatinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Docetaxel + Lapatinib DCLGGE5 Lapatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Docetaxel + Lapatinib DCVRS9R Lapatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Docetaxel + Lapatinib DCVYS4Y Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Docetaxel + Lapatinib DCJUS37 Lapatinib Glioblastoma (Cell Line: SNB-75) [3]
Docetaxel + Lapatinib DCUNV1Y Lapatinib Glioma (Cell Line: SF-539) [3]
Docetaxel + Lapatinib DC39VSH Lapatinib Glioma (Cell Line: SF-295) [3]
Docetaxel + Lapatinib DCCJ31K Lapatinib Glioma (Cell Line: SF-268) [3]
Docetaxel + Lapatinib DCZR14Y Lapatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Docetaxel + Lapatinib DCVSL3V Lapatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Docetaxel + Lapatinib DCHG9QR Lapatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Lapatinib DCTN7WO Lapatinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Docetaxel + Lapatinib DCQMRVP Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Docetaxel + Lapatinib DC99A6Q Lapatinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Docetaxel + Lapatinib DC7LUF1 Lapatinib Lung adenocarcinoma (Cell Line: EKVX) [3]
Docetaxel + Lapatinib DCUQLAC Lapatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Docetaxel + Lapatinib DCQORSE Lapatinib Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + Lapatinib DCKQFFA Lapatinib Malignant melanoma (Cell Line: LOX IMVI) [3]
Docetaxel + Lapatinib DCN5A0C Lapatinib Melanoma (Cell Line: MALME-3M) [3]
Docetaxel + Lapatinib DC9LZY9 Lapatinib Melanoma (Cell Line: UACC-257) [3]
Docetaxel + Lapatinib DCS5KHY Lapatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + Lapatinib DCEKZ3B Lapatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + Lapatinib DC2T3LE Lapatinib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Docetaxel + Lapatinib DC4E33P Lapatinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + Lapatinib DCDWB06 Lapatinib Prostate carcinoma (Cell Line: PC-3) [3]
Docetaxel + Terazosin DC9GMZ1 Terazosin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Epinephrine DC0H4OU Epinephrine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Chlorphenesin DC8CUEF Chlorphenesin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Artemether DC5RWNG Artemether Ewing sarcoma (Cell Line: TC-71) [3]
Docetaxel + PMID28460551-Compound-2 DCT7IDP PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + PMID28460551-Compound-2 DCCRMMG PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + PMID28460551-Compound-2 DCK1WGW PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + PMID28460551-Compound-2 DC164NC PMID28460551-Compound-2 Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Cyclophosphamide DC0S7OE Cyclophosphamide Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Cyclophosphamide DC57EOD Cyclophosphamide Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Docetaxel + Cyclophosphamide DC1WKXV Cyclophosphamide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Tacrine DCAZNFN Tacrine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Methotrexate DCGCQ6D Methotrexate Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + Methotrexate DC5174Y Methotrexate Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Methotrexate DCCHYQF Methotrexate Astrocytoma (Cell Line: U251) [3]
Docetaxel + Methotrexate DCXWL3S Methotrexate Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Methotrexate DCAIR3K Methotrexate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Methotrexate DCTK22R Methotrexate Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Methotrexate DCDN1DY Methotrexate Glioma (Cell Line: SF-539) [3]
Docetaxel + Methotrexate DCPKVHG Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Docetaxel + Methotrexate DCUUGVL Methotrexate Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Docetaxel + Methotrexate DCTVTJ4 Methotrexate Prostate carcinoma (Cell Line: PC-3) [3]
Docetaxel + Miglustat DCSD4VO Miglustat Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Mephenytoin DCGZ80E Mephenytoin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Arsenic trioxide DCD1VX8 Arsenic trioxide Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Arsenic trioxide DCPNUZC Arsenic trioxide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Docetaxel + Arsenic trioxide DCDC4MH Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Docetaxel + Arsenic trioxide DC9GRZH Arsenic trioxide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Docetaxel + Arsenic trioxide DC297E4 Arsenic trioxide Melanoma (Cell Line: SK-MEL-2) [3]
Docetaxel + Arsenic trioxide DCDNY9P Arsenic trioxide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + Arsenic trioxide DCE6JV4 Arsenic trioxide Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + Plicamycin DC6SU3F Plicamycin Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Plicamycin DC3K3OK Plicamycin Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + Plicamycin DCJGROJ Plicamycin Adenocarcinoma (Cell Line: A549) [3]
Docetaxel + Plicamycin DCITEWQ Plicamycin Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Plicamycin DC59IF1 Plicamycin Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Plicamycin DCLZRTY Plicamycin Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + Plicamycin DC5UKL1 Plicamycin Adenocarcinoma (Cell Line: SW-620) [3]
Docetaxel + Plicamycin DCJR3I9 Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + Plicamycin DCUK6B8 Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + Plicamycin DCXJF0J Plicamycin Amelanotic melanoma (Cell Line: M14) [3]
Docetaxel + Plicamycin DCP92YH Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Plicamycin DCGROZH Plicamycin Astrocytoma (Cell Line: U251) [3]
Docetaxel + Plicamycin DCHQ5HB Plicamycin Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Plicamycin DCPYOTD Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Docetaxel + Plicamycin DCYAIN7 Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Docetaxel + Plicamycin DCFUUTP Plicamycin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Docetaxel + Plicamycin DC23IUN Plicamycin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Docetaxel + Plicamycin DCXD051 Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Docetaxel + Plicamycin DC4V0EQ Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Plicamycin DCNQO0L Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Docetaxel + Plicamycin DC3QPL1 Plicamycin Glioblastoma (Cell Line: SNB-75) [3]
Docetaxel + Plicamycin DCO7ZX1 Plicamycin Glioma (Cell Line: SF-268) [3]
Docetaxel + Plicamycin DCZC0F8 Plicamycin Glioma (Cell Line: SF-539) [3]
Docetaxel + Plicamycin DC68L6I Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Docetaxel + Plicamycin DCL04HW Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Docetaxel + Plicamycin DCARLVQ Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Plicamycin DCYVB13 Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Docetaxel + Plicamycin DCT2YK7 Plicamycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Docetaxel + Plicamycin DCXLBJ9 Plicamycin Lung adenocarcinoma (Cell Line: EKVX) [3]
Docetaxel + Plicamycin DCNS8T1 Plicamycin Lung adenocarcinoma (Cell Line: HOP-62) [3]
Docetaxel + Plicamycin DCL1LA9 Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [3]
Docetaxel + Plicamycin DCT8MBX Plicamycin Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + Plicamycin DCFKYGM Plicamycin Melanoma (Cell Line: MALME-3M) [3]
Docetaxel + Plicamycin DCDBA47 Plicamycin Melanoma (Cell Line: SK-MEL-2) [3]
Docetaxel + Plicamycin DCQCINX Plicamycin Melanoma (Cell Line: UACC-257) [3]
Docetaxel + Plicamycin DCLCBMQ Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + Plicamycin DCLCHDR Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Docetaxel + Plicamycin DCOV46H Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + Plicamycin DCSCY7L Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Docetaxel + Plicamycin DC6UKJ6 Plicamycin Renal cell carcinoma (Cell Line: SN12C) [3]
Docetaxel + Testosterone DCKUIMM Testosterone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Triapine DCO4X1U Triapine Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Triapine DCK9ME9 Triapine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Triapine DCKV0GV Triapine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Docetaxel + Triapine DCO63B7 Triapine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Docetaxel + Triapine DC6DI3U Triapine Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Docetaxel + Triapine DC8R96W Triapine Glioma (Cell Line: SF-539) [3]
Docetaxel + Triapine DC8D1US Triapine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Triapine DC6JE2A Triapine Lung adenocarcinoma (Cell Line: EKVX) [3]
Docetaxel + Triapine DC65ABI Triapine Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Docetaxel + Triapine DCQBJR7 Triapine Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + Triapine DCGZ3XB Triapine Malignant melanoma (Cell Line: LOX IMVI) [3]
Docetaxel + Triapine DC1CUMN Triapine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + Tranexamic acid DCXLWKW Tranexamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + 10-hydroxycamptothecin DCR358L 10-hydroxycamptothecin Astrocytoma (Cell Line: U251) [3]
Docetaxel + 10-hydroxycamptothecin DCYHD90 10-hydroxycamptothecin Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + 10-hydroxycamptothecin DC0VIBR 10-hydroxycamptothecin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Dronedarone DCQSFAL Dronedarone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Topetecan DC8O82W Topetecan Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + Pralatrexate DCVMUJH Pralatrexate Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Pamidronate DCY32ER Pamidronate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Palonosetron DCN91PG Palonosetron Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Buspirone DCLBOPK Buspirone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Efavirenz DCZJ21Y Efavirenz Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Terameprocol DC3PUJ1 Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [3]
Docetaxel + Terameprocol DCHJOKA Terameprocol Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Terameprocol DCYQPW3 Terameprocol Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Terameprocol DCQ5SJ4 Terameprocol Adenocarcinoma (Cell Line: SW-620) [3]
Docetaxel + Terameprocol DCYRKUS Terameprocol Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + Terameprocol DCYZQQM Terameprocol Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Docetaxel + Terameprocol DCR9S6N Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + Terameprocol DCBF7JA Terameprocol Amelanotic melanoma (Cell Line: M14) [3]
Docetaxel + Terameprocol DCV36WD Terameprocol Astrocytoma (Cell Line: U251) [3]
Docetaxel + Terameprocol DC75FRR Terameprocol Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Terameprocol DCC1AGW Terameprocol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Docetaxel + Terameprocol DC42ZJK Terameprocol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Terameprocol DCMCA3M Terameprocol Chronic myelogenous leukemia (Cell Line: K-562) [3]
Docetaxel + Terameprocol DC9SJ8F Terameprocol Clear cell renal cell carcinoma (Cell Line: A498) [3]
Docetaxel + Terameprocol DCUMCW8 Terameprocol Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Docetaxel + Terameprocol DCNSAC0 Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Docetaxel + Terameprocol DCO4RWV Terameprocol Glioma (Cell Line: SF-268) [3]
Docetaxel + Terameprocol DCEPCYB Terameprocol Glioma (Cell Line: SF-295) [3]
Docetaxel + Terameprocol DC3K2QW Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Terameprocol DCEMISO Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Docetaxel + Terameprocol DCR3BJO Terameprocol Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Docetaxel + Terameprocol DCX9W8D Terameprocol Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Docetaxel + Terameprocol DC7R7D0 Terameprocol Malignant melanoma (Cell Line: LOX IMVI) [3]
Docetaxel + Terameprocol DCZY8HZ Terameprocol Melanoma (Cell Line: MALME-3M) [3]
Docetaxel + Terameprocol DCN8G6F Terameprocol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + Terameprocol DCGWNRT Terameprocol Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Docetaxel + Terameprocol DCW5A1V Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + Terameprocol DC0NZEH Terameprocol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Docetaxel + Guanfacine DCJ3V5J Guanfacine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + SCH 727965 DCQ99OW SCH 727965 Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + SCH 727965 DC5VSV2 SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [3]
Docetaxel + SCH 727965 DCXAQHZ SCH 727965 Adenocarcinoma (Cell Line: A549) [3]
Docetaxel + SCH 727965 DC7IKM8 SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + SCH 727965 DCURJAN SCH 727965 Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + SCH 727965 DCAVW1C SCH 727965 Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + SCH 727965 DCMJ4IR SCH 727965 Adenocarcinoma (Cell Line: SW-620) [3]
Docetaxel + SCH 727965 DC8JR68 SCH 727965 Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + SCH 727965 DC0RTOW SCH 727965 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Docetaxel + SCH 727965 DCU1BBK SCH 727965 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + SCH 727965 DC0HSVA SCH 727965 Amelanotic melanoma (Cell Line: M14) [3]
Docetaxel + SCH 727965 DC0ALCE SCH 727965 Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + SCH 727965 DCJLFSH SCH 727965 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + SCH 727965 DCTOSZO SCH 727965 Astrocytoma (Cell Line: U251) [3]
Docetaxel + SCH 727965 DCQ1WGR SCH 727965 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + SCH 727965 DCIEX6G SCH 727965 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Docetaxel + SCH 727965 DC1G6NX SCH 727965 Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Docetaxel + SCH 727965 DCAPDBS SCH 727965 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Docetaxel + SCH 727965 DCNYRPX SCH 727965 Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Docetaxel + SCH 727965 DC2CF3A SCH 727965 Glioma (Cell Line: SF-295) [3]
Docetaxel + SCH 727965 DCUN8VS SCH 727965 Glioma (Cell Line: SF-539) [3]
Docetaxel + SCH 727965 DC9ZR80 SCH 727965 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + SCH 727965 DCTHI25 SCH 727965 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Docetaxel + SCH 727965 DC9QUCR SCH 727965 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Docetaxel + SCH 727965 DCL3IVZ SCH 727965 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Docetaxel + SCH 727965 DCIXC5E SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Docetaxel + SCH 727965 DCS9SWQ SCH 727965 Lung adenocarcinoma (Cell Line: HOP-62) [3]
Docetaxel + SCH 727965 DCOHVON SCH 727965 Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Docetaxel + SCH 727965 DCNG8BL SCH 727965 Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + SCH 727965 DCMBKDC SCH 727965 Malignant melanoma (Cell Line: LOX IMVI) [3]
Docetaxel + SCH 727965 DCB189C SCH 727965 Melanoma (Cell Line: UACC-257) [3]
Docetaxel + SCH 727965 DCAEM0D SCH 727965 Melanoma (Cell Line: MALME-3M) [3]
Docetaxel + SCH 727965 DC1SD9J SCH 727965 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + SCH 727965 DC2N59F SCH 727965 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + SCH 727965 DCAEI5S SCH 727965 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + SCH 727965 DCLXB39 SCH 727965 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Docetaxel + SCH 727965 DCOQA8Q SCH 727965 Prostate carcinoma (Cell Line: PC-3) [3]
Docetaxel + Ifosfamide DCVSPZF Ifosfamide Adenocarcinoma (Cell Line: OVCAR3) [3]
Docetaxel + Ifosfamide DCDN1H2 Ifosfamide Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Ifosfamide DC8A0UW Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Docetaxel + Ifosfamide DC0IA3B Ifosfamide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Ifosfamide DCGNNY3 Ifosfamide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Docetaxel + Ifosfamide DCJSI7X Ifosfamide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + Ifosfamide DCI9AOA Ifosfamide Renal cell carcinoma (Cell Line: SN12C) [3]
Docetaxel + Ursodeoxycholic acid DCDHBSR Ursodeoxycholic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Memantine DCAT0IY Memantine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Methoxsalen DCR2R75 Methoxsalen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + JZL195 DCUYKVC JZL195 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Sulfinpyrazone DCBETH2 Sulfinpyrazone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Bendamustine hydrochloride DCDCQ4G Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [3]
Docetaxel + Bendamustine hydrochloride DC92KP7 Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Bendamustine hydrochloride DCTYL2K Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Docetaxel + Bendamustine hydrochloride DCW1O4S Bendamustine hydrochloride Glioma (Cell Line: SF-539) [3]
Docetaxel + Bendamustine hydrochloride DCWJOCV Bendamustine hydrochloride Glioma (Cell Line: SF-295) [3]
Docetaxel + Bendamustine hydrochloride DCG3ZX6 Bendamustine hydrochloride Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Docetaxel + Bendamustine hydrochloride DCC72KU Bendamustine hydrochloride Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + Sitagliptin DCRB7KG Sitagliptin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Mitomycin DC0VNZF Mitomycin Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Mitomycin DCBHTL3 Mitomycin Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Mitomycin DCHDXCB Mitomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Docetaxel + Mitomycin DCW1QOU Mitomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + Mitomycin DC51LF1 Mitomycin Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Mitomycin DCVK52L Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [3]
Docetaxel + Mitomycin DCMRKFC Mitomycin Glioma (Cell Line: SF-539) [3]
Docetaxel + Mitomycin DCVBOCT Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Naringenin DCZMWSC Naringenin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Pentamidine DCCV3C0 Pentamidine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Bosentan DCMJLPF Bosentan Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Cabozantinib DCWIRRJ Cabozantinib Ewing sarcoma (Cell Line: TC-71) [3]
Docetaxel + Triflupromazine DCE717Y Triflupromazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Norcisapride DCX74JO Norcisapride Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Isoproterenol DCKTZ2Q Isoproterenol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Trifluoperazine DC3XUGS Trifluoperazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Altretamine DCT390J Altretamine Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Altretamine DCWKW49 Altretamine Adenocarcinoma (Cell Line: SW-620) [3]
Docetaxel + Altretamine DCO3SYH Altretamine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Altretamine DCNNIRS Altretamine Clear cell renal cell carcinoma (Cell Line: A498) [3]
Docetaxel + Altretamine DCLOKC7 Altretamine Melanoma (Cell Line: UACC-257) [3]
Docetaxel + Oseltamivir DCPN0GK Oseltamivir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Tamoxifen DCLQ7XB Tamoxifen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Entacapone DCR0RU9 Entacapone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + TEM DCVMKQR TEM Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + TEM DCAYZPH TEM Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + TEM DCW6D3B TEM Adenocarcinoma (Cell Line: A549) [3]
Docetaxel + TEM DCBZCY4 TEM Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + TEM DCM63NK TEM Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + TEM DCTJQ77 TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + TEM DCQ1Z0F TEM Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + TEM DC0EI81 TEM Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + TEM DC2DWMP TEM Glioblastoma (Cell Line: SNB-75) [3]
Docetaxel + TEM DCXI9AB TEM Glioma (Cell Line: SF-268) [3]
Docetaxel + TEM DC1M1XR TEM High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Docetaxel + TEM DCIDAJJ TEM High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Docetaxel + TEM DCMXWFN TEM Lung adenocarcinoma (Cell Line: HOP-62) [3]
Docetaxel + TEM DCFHE0D TEM Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + TEM DCV9UZ2 TEM Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + TEM DC4R28R TEM Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Docetaxel + TEM DCUEMAW TEM Prostate carcinoma (Cell Line: PC-3) [3]
Docetaxel + Allopurinol DC2GISP Allopurinol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Benserazide DC4V7RR Benserazide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Pargyline DC4J4D5 Pargyline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Idarubicin DCCPWO5 Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Docetaxel + Epothilone B DCK11BY Epothilone B Hepatoblastoma (Cell Line: HB3) [3]
Docetaxel + Darunavir DC9ZTDG Darunavir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Bleomycin DCD06SR Bleomycin Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Bleomycin DCXL5BZ Bleomycin Amelanotic melanoma (Cell Line: M14) [3]
Docetaxel + Bleomycin DC3PLSF Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Bleomycin DCWH0L5 Bleomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Docetaxel + Bleomycin DCGGES7 Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Bleomycin DC3YW31 Bleomycin Glioma (Cell Line: SF-295) [3]
Docetaxel + Bleomycin DCC3B3P Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [3]
Docetaxel + Bleomycin DC2UNN7 Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [3]
Docetaxel + Pramipexole DCDX8EM Pramipexole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Methylene blue DCO37O7 Methylene blue Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Olanzapine DCZ1PAJ Olanzapine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Maprotiline DCLX1SQ Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole DCT66CO 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + NITD609 DCYBBV8 NITD609 DD2 (Cell Line: DD2) [3]
Docetaxel + Acetohexamide DCND4ZL Acetohexamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Cisplatin DCQR8O0 Cisplatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + Cisplatin DCTE5B8 Cisplatin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Docetaxel + Cisplatin DCRPUOU Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Cisplatin DCGH4JH Cisplatin Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + Theophylline DCVIY8A Theophylline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Chlorambucil DCUMRAO Chlorambucil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Chlorambucil DC8CK60 Chlorambucil Lung adenocarcinoma (Cell Line: HOP-62) [3]
Docetaxel + Amantadine DCIXFL3 Amantadine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Sorafenib DCA27SC Sorafenib Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Sorafenib DCPVH4D Sorafenib Adenocarcinoma (Cell Line: A549) [3]
Docetaxel + Sorafenib DCMCT2I Sorafenib Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + Sorafenib DC4N0PP Sorafenib Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Sorafenib DC6ZBOE Sorafenib Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Sorafenib DCJU6GE Sorafenib Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + Sorafenib DCWWR06 Sorafenib Amelanotic melanoma (Cell Line: M14) [3]
Docetaxel + Sorafenib DCLPU1U Sorafenib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + Sorafenib DC3R9M9 Sorafenib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Sorafenib DCHNR29 Sorafenib Astrocytoma (Cell Line: U251) [3]
Docetaxel + Sorafenib DCWWCJ9 Sorafenib Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Sorafenib DCBDNZD Sorafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Docetaxel + Sorafenib DCIZRNG Sorafenib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Docetaxel + Sorafenib DC5NA6P Sorafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Docetaxel + Sorafenib DCAUVVZ Sorafenib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Docetaxel + Sorafenib DC68A2R Sorafenib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Sorafenib DCTQ5I4 Sorafenib Glioblastoma (Cell Line: SNB-75) [3]
Docetaxel + Sorafenib DC9CC7Z Sorafenib Glioma (Cell Line: SF-539) [3]
Docetaxel + Sorafenib DCRFEZA Sorafenib Glioma (Cell Line: SF-295) [3]
Docetaxel + Sorafenib DCQ323L Sorafenib Glioma (Cell Line: SF-268) [3]
Docetaxel + Sorafenib DCCCCSE Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Docetaxel + Sorafenib DCV7DEI Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Docetaxel + Sorafenib DCNCG98 Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Sorafenib DC98PFW Sorafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Docetaxel + Sorafenib DCKG7TD Sorafenib Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + Sorafenib DCZA5TY Sorafenib Melanoma (Cell Line: SK-MEL-2) [3]
Docetaxel + Sorafenib DC8S413 Sorafenib Melanoma (Cell Line: UACC-257) [3]
Docetaxel + Sorafenib DCSYSYQ Sorafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + Sorafenib DCZJYXL Sorafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + Sorafenib DCF6PA8 Sorafenib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Docetaxel + Sorafenib DC717XR Sorafenib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + Sorafenib DCZEY3J Sorafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Docetaxel + Sorafenib DCEQBV2 Sorafenib Prostate carcinoma (Cell Line: PC-3) [3]
Docetaxel + Sorafenib DCM7R4M Sorafenib Renal cell carcinoma (Cell Line: SN12C) [3]
Docetaxel + ER819762 DC3NRGN ER819762 Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + ER819762 DCHYKEC ER819762 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Docetaxel + Romidepsin DCCAR0E Romidepsin Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + Romidepsin DCLJKIM Romidepsin Glioma (Cell Line: SF-539) [3]
Docetaxel + Romidepsin DCWCD63 Romidepsin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + Azacitidine DC396D9 Azacitidine Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Azacitidine DCT6OHD Azacitidine Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + Azacitidine DC8U7BJ Azacitidine Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + Azacitidine DC1J5FI Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Azacitidine DCGJQ6F Azacitidine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Docetaxel + Azacitidine DCLRHKH Azacitidine Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + Loperamide DC0TN6B Loperamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Pomalidomide DC4PD1Z Pomalidomide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Docetaxel + Pomalidomide DC7E345 Pomalidomide Glioma (Cell Line: SF-295) [3]
Docetaxel + Maraviroc DCFB3PK Maraviroc Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Mercaptopurine DC25QN0 Mercaptopurine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Docetaxel + Mercaptopurine DC7RR88 Mercaptopurine Renal cell carcinoma (Cell Line: UO-31) [3]
Docetaxel + Chlormezanone DCJH6FR Chlormezanone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Endoxifen DCY4W67 Endoxifen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Hydralazine DCE8N7A Hydralazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Mepacrine DCV2O7G Mepacrine Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Elacridar DCPRU6Y Elacridar Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11) [3]
Docetaxel + Mefloquine DC2Q3BT Mefloquine DD2 (Cell Line: DD2) [3]
Docetaxel + JTC-801 DCL04PL JTC-801 DD2 (Cell Line: DD2) [3]
Docetaxel + Lacosamide DCMXP9E Lacosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Zileuton DC2ERZQ Zileuton Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Nabilone DC1WME7 Nabilone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Nitisinone DC01LIP Nitisinone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Silver sulfadiazine DC67I5Z Silver sulfadiazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Olmesartan medoxomil DCAMN8S Olmesartan medoxomil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Rufinamide DC53AWL Rufinamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + PMID28870136-Compound-43 DCJG1U3 PMID28870136-Compound-43 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + PMID28870136-Compound-43 DC87L42 PMID28870136-Compound-43 Prostate carcinoma (Cell Line: PC-3) [3]
Docetaxel + FORMESTANE DCBRSH2 FORMESTANE Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Aminolevulinic Acid Hydrochloride DCUCUWK Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + Aminolevulinic Acid Hydrochloride DCL10C2 Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + Aminolevulinic Acid Hydrochloride DCW4SS0 Aminolevulinic Acid Hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Aminolevulinic Acid Hydrochloride DCI06D4 Aminolevulinic Acid Hydrochloride Glioma (Cell Line: SF-539) [3]
Docetaxel + Metaxalone DCJCNUV Metaxalone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Busulfan DCO7GJI Busulfan Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Hydroxychloroquine DCKJSSN Hydroxychloroquine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Atovaquone DC407GM Atovaquone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + ML323 DCWL9L8 ML323 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Enoxacin DC360F8 Enoxacin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Raltegravir DCV9D2P Raltegravir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Acetohydroxamic Acid DCRQYWN Acetohydroxamic Acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Ibrutinib DCDM5FX Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [3]
Docetaxel + GSK2194069 DCL2IL6 GSK2194069 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Dasatinib DCGL0TV Dasatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Docetaxel + Dasatinib DCC9SI2 Dasatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + Dasatinib DCNOYH3 Dasatinib Astrocytoma (Cell Line: U251) [3]
Docetaxel + Dasatinib DCF61TG Dasatinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Dasatinib DCQ6C5G Dasatinib Glioma (Cell Line: SF-539) [3]
Docetaxel + Dasatinib DC5WK6D Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Docetaxel + Etomidate DCPMS0W Etomidate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + L-165041 DC7U00N L-165041 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Docetaxel + Lapatinib DC4DNP0 Lapatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Lapatinib DCRWPMI Lapatinib Carcinoma (Cell Line: RXF 393) [4]
Docetaxel + Lapatinib DC9IQZD Lapatinib Carcinoma (Cell Line: MCF7) [4]
Docetaxel + Lapatinib DCOD7JZ Lapatinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + Lapatinib DCX0WP7 Lapatinib Colon carcinoma (Cell Line: KM12) [4]
Docetaxel + Lapatinib DCI9H2I Lapatinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Docetaxel + Lapatinib DCUJ54V Lapatinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + Lapatinib DCSIW26 Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Cyclophosphamide DC612QV Cyclophosphamide Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Cyclophosphamide DCFH08P Cyclophosphamide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Methotrexate DCUYT17 Methotrexate Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Arsenic trioxide DCX834M Arsenic trioxide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Plicamycin DCYUCCS Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Plicamycin DCFZ6J5 Plicamycin Carcinoma (Cell Line: RXF 393) [4]
Docetaxel + Plicamycin DCUEJJ1 Plicamycin Carcinoma (Cell Line: MCF7) [4]
Docetaxel + Plicamycin DC68T3T Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + Plicamycin DCWB3PR Plicamycin Colon carcinoma (Cell Line: KM12) [4]
Docetaxel + Plicamycin DCTHWH0 Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Docetaxel + Plicamycin DCXWS4S Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + Triapine DCAQ9DV Triapine Colon carcinoma (Cell Line: KM12) [4]
Docetaxel + Triapine DCJSWTU Triapine Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + Pralatrexate DC5S2KG Pralatrexate Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + Terameprocol DC5MWRB Terameprocol Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Terameprocol DCJSNPD Terameprocol Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + SCH 727965 DCSS0Y9 SCH 727965 Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + SCH 727965 DC3D3JO SCH 727965 Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + SCH 727965 DC822OJ SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + SCH 727965 DCSUB8K SCH 727965 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Docetaxel + Bendamustine hydrochloride DCCXMUB Bendamustine hydrochloride Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Bendamustine hydrochloride DC9JKE1 Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Mitomycin DC8H4XB Mitomycin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + TEM DCPMIFU TEM Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + TEM DCK0H2X TEM Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + TEM DCRE9KD TEM Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Docetaxel + Bleomycin DCPUWUR Bleomycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Docetaxel + Bleomycin DCTA56S Bleomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + Cisplatin DCI5CAO Cisplatin Carcinoma (Cell Line: RXF 393) [4]
Docetaxel + Sorafenib DCKVT07 Sorafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Sorafenib DCB9QEH Sorafenib Carcinoma (Cell Line: RXF 393) [4]
Docetaxel + Sorafenib DCIN5IS Sorafenib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + Sorafenib DCCFQ6X Sorafenib Colon carcinoma (Cell Line: KM12) [4]
Docetaxel + Sorafenib DCNOJJD Sorafenib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Docetaxel + Sorafenib DCTVFRF Sorafenib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + Sorafenib DC6U2KU Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Azacitidine DCYIUHE Azacitidine Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + Pomalidomide DCYJINE Pomalidomide Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Pomalidomide DCOECW6 Pomalidomide Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + Pomalidomide DCUV2OZ Pomalidomide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Busulfan DCESKZX Busulfan Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + Dasatinib DC7XTB5 Dasatinib Carcinoma (Cell Line: RXF 393) [4]
Docetaxel + Dasatinib DCRUVZS Dasatinib Colon carcinoma (Cell Line: KM12) [4]
Docetaxel + Dasatinib DCUSIID Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Dopamine + Docetaxel DC7FI8H Dopamine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Doxapram + Docetaxel DCYNMLU Doxapram Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Doxepin + Docetaxel DCN7JVC Doxepin Hepatoblastoma (Cell Line: HB3) [5]
Doxorubicin + Docetaxel DCBZMXA Doxorubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Eflornithine + Docetaxel DCHW2YX Eflornithine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Emetine + Docetaxel DCETAUO Emetine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Epirubicin + Docetaxel DCUFO0R Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Epirubicin + Docetaxel DC70BUX Epirubicin Renal cell carcinoma (Cell Line: UO-31) [3]
Epirubicin + Docetaxel DCX8DG2 Epirubicin Adenocarcinoma (Cell Line: A549) [5]
Epirubicin + Docetaxel DCJ0Q14 Epirubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Epirubicin + Docetaxel DCD6AAT Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Epirubicin + Docetaxel DCFNDE5 Epirubicin Prostate carcinoma (Cell Line: PC-3) [5]
Epothilone B + Docetaxel DCED7KX Epothilone B DD2 (Cell Line: DD2) [3]
Epothilone B + Docetaxel DC0IMAN Epothilone B Hepatoblastoma (Cell Line: HB3) [5]
Eptifibatide + Docetaxel DCDCBH9 Eptifibatide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Estramustine + Docetaxel DCU6B3V Estramustine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Estramustine + Docetaxel DCHM2Z4 Estramustine Adenocarcinoma (Cell Line: NCIH23) [5]
Estramustine + Docetaxel DCFONZU Estramustine Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
ETHISTERONE + Docetaxel DC05NBI ETHISTERONE Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Everolimus + Docetaxel DCSOV8Z Everolimus Ewing sarcoma (Cell Line: TC-71) [3]
Ezetimibe + Docetaxel DCCH5GE Ezetimibe Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Fibrates + Docetaxel DCB0VA8 Fibrates Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Flavonoid derivative 1 + Docetaxel DC6WW39 Flavonoid derivative 1 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Fludarabine + Docetaxel DC7VCSX Fludarabine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fludarabine + Docetaxel DCUX23H Fludarabine Colon carcinoma (Cell Line: KM12) [4]
Fludarabine + Docetaxel DC8HM8U Fludarabine Adenocarcinoma (Cell Line: HT29) [5]
Fludarabine + Docetaxel DCP9JFU Fludarabine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Fludarabine + Docetaxel DCR38QX Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Fludarabine + Docetaxel DCHE063 Fludarabine Melanoma (Cell Line: MALME-3M) [5]
Fluspirilene + Docetaxel DC7RH78 Fluspirilene Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Fomepizole + Docetaxel DCGYYBO Fomepizole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
FORMESTANE + Docetaxel DCTJYTW FORMESTANE Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Formononetin + Docetaxel DC152NI Formononetin Ewing sarcoma (Cell Line: TC-71) [3]
Fosfomycin + Docetaxel DCDIM8O Fosfomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Fulvestrant + Docetaxel DCJU91O Fulvestrant Adenocarcinoma (Cell Line: DU-145) [3]
Fulvestrant + Docetaxel DCX14J4 Fulvestrant Adenocarcinoma (Cell Line: OVCAR3) [3]
Fulvestrant + Docetaxel DCMXRJN Fulvestrant Adenocarcinoma (Cell Line: NCIH23) [3]
Fulvestrant + Docetaxel DCBS161 Fulvestrant Adenocarcinoma (Cell Line: A549) [3]
Fulvestrant + Docetaxel DCBGP2P Fulvestrant Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Docetaxel DC33QHU Fulvestrant Adenocarcinoma (Cell Line: HCT116) [3]
Fulvestrant + Docetaxel DC5EEFN Fulvestrant Adenocarcinoma (Cell Line: SW-620) [3]
Fulvestrant + Docetaxel DCN0Y39 Fulvestrant Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fulvestrant + Docetaxel DCY7ICB Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fulvestrant + Docetaxel DCH7DLU Fulvestrant Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Fulvestrant + Docetaxel DC8POLS Fulvestrant Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fulvestrant + Docetaxel DC1PQHT Fulvestrant Astrocytoma (Cell Line: U251) [3]
Fulvestrant + Docetaxel DC5OZGE Fulvestrant Astrocytoma (Cell Line: SNB-19) [3]
Fulvestrant + Docetaxel DC221RR Fulvestrant Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fulvestrant + Docetaxel DCKQ47I Fulvestrant Clear cell renal cell carcinoma (Cell Line: A498) [3]
Fulvestrant + Docetaxel DCOIPO2 Fulvestrant Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Fulvestrant + Docetaxel DCU1X4B Fulvestrant Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Fulvestrant + Docetaxel DC68VUF Fulvestrant Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Fulvestrant + Docetaxel DCAE6R3 Fulvestrant Glioma (Cell Line: SF-539) [3]
Fulvestrant + Docetaxel DC0G8W7 Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Fulvestrant + Docetaxel DCZM47C Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Fulvestrant + Docetaxel DC5BV1M Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Fulvestrant + Docetaxel DCOBXV7 Fulvestrant Lung adenocarcinoma (Cell Line: EKVX) [3]
Fulvestrant + Docetaxel DC0V8MT Fulvestrant Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Fulvestrant + Docetaxel DC7YSSV Fulvestrant Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Fulvestrant + Docetaxel DCN5C7M Fulvestrant Malignant melanoma (Cell Line: UACC62) [3]
Fulvestrant + Docetaxel DCUHMH5 Fulvestrant Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Fulvestrant + Docetaxel DCFQL4P Fulvestrant Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Fulvestrant + Docetaxel DC5MNY4 Fulvestrant Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fulvestrant + Docetaxel DCF52CA Fulvestrant Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Fulvestrant + Docetaxel DC6ZF04 Fulvestrant Renal cell carcinoma (Cell Line: SN12C) [3]
Fulvestrant + Docetaxel DCRAHQB Fulvestrant Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Fulvestrant + Docetaxel DCQE7FZ Fulvestrant Carcinoma (Cell Line: MCF7) [4]
Fulvestrant + Docetaxel DCKZXZ6 Fulvestrant Colon adenocarcinoma (Cell Line: COLO 205) [4]
Fulvestrant + Docetaxel DCZICAX Fulvestrant Colon carcinoma (Cell Line: KM12) [4]
Furazolidone + Docetaxel DCB526Q Furazolidone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Docetaxel DCTAROO Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Docetaxel DCQ2E8C Gefitinib Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Docetaxel DCDASEZ Gefitinib Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Docetaxel DC8ZSCE Gefitinib Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Docetaxel DC40O27 Gefitinib Adenocarcinoma (Cell Line: HCT-15) [3]
Gefitinib + Docetaxel DC531EA Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Docetaxel DC5PNQN Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Docetaxel DCF14U9 Gefitinib Astrocytoma (Cell Line: U251) [3]
Gefitinib + Docetaxel DCCPR4O Gefitinib Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Docetaxel DCPCFSN Gefitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + Docetaxel DCCA201 Gefitinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Docetaxel DCCAPAF Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Docetaxel DC9H9AF Gefitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Docetaxel DCZ9NHW Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Docetaxel DC5CEYN Gefitinib Glioblastoma (Cell Line: SNB-75) [3]
Gefitinib + Docetaxel DCWFUVY Gefitinib Glioma (Cell Line: SF-268) [3]
Gefitinib + Docetaxel DCQKRDK Gefitinib Glioma (Cell Line: SF-295) [3]
Gefitinib + Docetaxel DCAF889 Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Docetaxel DC5I2KF Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Docetaxel DCLF9CG Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Docetaxel DCA8H3K Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Docetaxel DCNGDNZ Gefitinib Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Docetaxel DCDGTNF Gefitinib Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Docetaxel DCV04ML Gefitinib Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Docetaxel DCLWVGK Gefitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Docetaxel DC62LJV Gefitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Docetaxel DC8RBHA Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Docetaxel DC1HWTF Gefitinib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Docetaxel DCRFWGG Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Docetaxel DCYOPCJ Gefitinib Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Docetaxel DCAB6VU Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
GINKGOLIDE A + Docetaxel DCPCO8W GINKGOLIDE A Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
GYKI-52466 + Docetaxel DCA4GA9 GYKI-52466 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Hepzato + Docetaxel DC2BX6V Hepzato Clear cell renal cell carcinoma (Cell Line: A498) [3]
Hepzato + Docetaxel DC5GZU0 Hepzato Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Hepzato + Docetaxel DCEJRSF Hepzato Renal cell carcinoma (Cell Line: SN12C) [3]
Hepzato + Docetaxel DCWESJZ Hepzato Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Hepzato + Docetaxel DCXN7N1 Hepzato Adenocarcinoma (Cell Line: DU-145) [5]
Hepzato + Docetaxel DCDZN9Z Hepzato Adenocarcinoma (Cell Line: OVCAR3) [5]
Hepzato + Docetaxel DC3LB7M Hepzato Adenocarcinoma (Cell Line: NCIH23) [5]
Hepzato + Docetaxel DC39ZBH Hepzato Adenocarcinoma (Cell Line: SW-620) [5]
Hepzato + Docetaxel DCKDOHX Hepzato Adenocarcinoma (Cell Line: HT29) [5]
Hepzato + Docetaxel DC53VZY Hepzato Adenocarcinoma (Cell Line: HCC-2998) [5]
Hepzato + Docetaxel DCG3PQO Hepzato Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Hepzato + Docetaxel DCUBVTY Hepzato Lung adenocarcinoma (Cell Line: EKVX) [5]
Hydralazine + Docetaxel DCNDUC8 Hydralazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Ibutilide + Docetaxel DCY4F9G Ibutilide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Idarubicin + Docetaxel DCAL0KN Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [5]
Iloprost + Docetaxel DC9L78Z Iloprost Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Imatinib + Docetaxel DCHZEE0 Imatinib Adenocarcinoma (Cell Line: DU-145) [3]
Imatinib + Docetaxel DCCE2O9 Imatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Imatinib + Docetaxel DC4P5OX Imatinib Adenocarcinoma (Cell Line: NCIH23) [3]
Imatinib + Docetaxel DCAQJG2 Imatinib Adenocarcinoma (Cell Line: A549) [3]
Imatinib + Docetaxel DC4KV1C Imatinib Adenocarcinoma (Cell Line: HCT-15) [3]
Imatinib + Docetaxel DCQBI4Q Imatinib Adenocarcinoma (Cell Line: SW-620) [3]
Imatinib + Docetaxel DCWE1YG Imatinib Adenocarcinoma (Cell Line: HCT116) [3]
Imatinib + Docetaxel DC9ICQZ Imatinib Adenocarcinoma (Cell Line: HT29) [3]
Imatinib + Docetaxel DCPVNGG Imatinib Adenocarcinoma (Cell Line: HCC-2998) [3]
Imatinib + Docetaxel DCR6DKU Imatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Imatinib + Docetaxel DC5LVK0 Imatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Imatinib + Docetaxel DCX0ONH Imatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Imatinib + Docetaxel DCPG3T0 Imatinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Imatinib + Docetaxel DCYOOYJ Imatinib Astrocytoma (Cell Line: U251) [3]
Imatinib + Docetaxel DCZYRT1 Imatinib Astrocytoma (Cell Line: SNB-19) [3]
Imatinib + Docetaxel DC7RAUQ Imatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Imatinib + Docetaxel DC08XQ7 Imatinib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Imatinib + Docetaxel DCSVNRK Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Imatinib + Docetaxel DCTFEYU Imatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Imatinib + Docetaxel DCOZ6KM Imatinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Imatinib + Docetaxel DCM446X Imatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Imatinib + Docetaxel DC6WTW8 Imatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Imatinib + Docetaxel DCKNOVI Imatinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Imatinib + Docetaxel DCAWVQ1 Imatinib Glioblastoma (Cell Line: SNB-75) [3]
Imatinib + Docetaxel DCG9YJ5 Imatinib Glioma (Cell Line: SF-539) [3]
Imatinib + Docetaxel DCQCQ04 Imatinib Glioma (Cell Line: SF-295) [3]
Imatinib + Docetaxel DCCIO5D Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Imatinib + Docetaxel DCHMED2 Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Imatinib + Docetaxel DC28NQ7 Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Imatinib + Docetaxel DC3TX6Q Imatinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Imatinib + Docetaxel DCJPF23 Imatinib Lung adenocarcinoma (Cell Line: EKVX) [3]
Imatinib + Docetaxel DCJ0M16 Imatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Imatinib + Docetaxel DCM930N Imatinib Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Imatinib + Docetaxel DC2RFXJ Imatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Imatinib + Docetaxel DCZS5WD Imatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Imatinib + Docetaxel DCLEPQO Imatinib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Imatinib + Docetaxel DC974EG Imatinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Imatinib + Docetaxel DCU59V1 Imatinib Prostate carcinoma (Cell Line: PC-3) [3]
Imatinib + Docetaxel DCHA01E Imatinib Renal cell carcinoma (Cell Line: SN12C) [3]
Imatinib + Docetaxel DCVE4C7 Imatinib Renal cell carcinoma (Cell Line: UO-31) [3]
Imatinib + Docetaxel DCUT1KL Imatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Imatinib + Docetaxel DCZKSNZ Imatinib Carcinoma (Cell Line: RXF 393) [4]
Imatinib + Docetaxel DCODCOM Imatinib Carcinoma (Cell Line: MCF7) [4]
Imatinib + Docetaxel DCKJ0MM Imatinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Imatinib + Docetaxel DC23644 Imatinib Colon carcinoma (Cell Line: KM12) [4]
Imatinib + Docetaxel DCZJP6T Imatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Imatinib + Docetaxel DC4WO2Q Imatinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Imatinib + Docetaxel DC978KK Imatinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Imipramine + Docetaxel DCQQ1VG Imipramine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Indazole derivative 5 + Docetaxel DCM2RXB Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Indazole derivative 5 + Docetaxel DCOBZIS Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Indazole derivative 5 + Docetaxel DCM919Y Indazole derivative 5 Astrocytoma (Cell Line: U251) [3]
Indazole derivative 5 + Docetaxel DCXMRLK Indazole derivative 5 Astrocytoma (Cell Line: SNB-19) [3]
Indazole derivative 5 + Docetaxel DCVP74X Indazole derivative 5 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Indazole derivative 5 + Docetaxel DCG3HLH Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Indazole derivative 5 + Docetaxel DC63PSK Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Indazole derivative 5 + Docetaxel DCEDNOS Indazole derivative 5 Adenocarcinoma (Cell Line: A549) [5]
Indazole derivative 5 + Docetaxel DC2JHYX Indazole derivative 5 Adenocarcinoma (Cell Line: SW-620) [5]
Indazole derivative 5 + Docetaxel DCC1UPW Indazole derivative 5 Adenocarcinoma (Cell Line: HCC-2998) [5]
Indazole derivative 5 + Docetaxel DCGPDQ1 Indazole derivative 5 Adenocarcinoma (Cell Line: HCT-15) [5]
Indazole derivative 5 + Docetaxel DCUGV99 Indazole derivative 5 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Indazole derivative 5 + Docetaxel DCWEOOZ Indazole derivative 5 Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Isosorbide dinitrate + Docetaxel DCTEBCA Isosorbide dinitrate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
JNK-IN-8 + Docetaxel DCVZUF5 JNK-IN-8 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
JNK-IN-8 + Docetaxel DCBVRRC JNK-IN-8 Amelanotic melanoma (Cell Line: M14) [5]
K-134 + Docetaxel DC3MRAN K-134 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Kanamycin + Docetaxel DCZ0Z9R Kanamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Lefaxin + Docetaxel DCO5SO1 Lefaxin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Lenalidomide + Docetaxel DCU8GGJ Lenalidomide Melanoma (Cell Line: MALME-3M) [5]
Lenvatinib + Docetaxel DC91SOL Lenvatinib Ewing sarcoma (Cell Line: TC-71) [3]
Letrozole + Docetaxel DCUEYC8 Letrozole Lung adenocarcinoma (Cell Line: EKVX) [3]
Levamisole + Docetaxel DC2RSF3 Levamisole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
LIAROZOLE + Docetaxel DC6D0LE LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
LIAROZOLE + Docetaxel DCRXE6L LIAROZOLE Chronic myelogenous leukemia (Cell Line: K-562) [3]
LIAROZOLE + Docetaxel DCPDVAY LIAROZOLE Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
LIAROZOLE + Docetaxel DCERS0H LIAROZOLE Clear cell renal cell carcinoma (Cell Line: A498) [3]
LIAROZOLE + Docetaxel DC8ZVET LIAROZOLE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
LIAROZOLE + Docetaxel DC2E5MW LIAROZOLE Adenocarcinoma (Cell Line: DU-145) [5]
LIAROZOLE + Docetaxel DC63M9X LIAROZOLE Adenocarcinoma (Cell Line: HT29) [5]
LIAROZOLE + Docetaxel DCK0AE8 LIAROZOLE Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
LIAROZOLE + Docetaxel DCVZKPZ LIAROZOLE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
LIAROZOLE + Docetaxel DCXB1JR LIAROZOLE Lung adenocarcinoma (Cell Line: EKVX) [5]
LIAROZOLE + Docetaxel DCAK25Q LIAROZOLE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
LIAROZOLE + Docetaxel DCBH0VD LIAROZOLE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Lithium Citrate + Docetaxel DC1HNF2 Lithium Citrate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Lumefantrine + Docetaxel DCQP6RV Lumefantrine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
LY03004 + Docetaxel DCX9T72 LY03004 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mebendazole + Docetaxel DCOH1YN Mebendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mebutamate + Docetaxel DCV9TQ6 Mebutamate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mechlorethamine + Docetaxel DCPHRJA Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Mechlorethamine + Docetaxel DCRZLY1 Mechlorethamine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Mesalazine + Docetaxel DCBMYHG Mesalazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Metaxalone + Docetaxel DCPDTM1 Metaxalone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Methocarbamol + Docetaxel DCLCHRD Methocarbamol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Methylergonovine + Docetaxel DCGU56G Methylergonovine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Metyrosine + Docetaxel DCOV7P6 Metyrosine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Miconazole + Docetaxel DC4XZI5 Miconazole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Miconazole + Docetaxel DCUROLB Miconazole DD2 (Cell Line: DD2) [3]
Mitomycin + Docetaxel DCJN23U Mitomycin Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Docetaxel DCJ5WF6 MK-1775 Ewing sarcoma (Cell Line: TC-71) [3]
MK-2206 + Docetaxel DCTGOTV MK-2206 Ewing sarcoma (Cell Line: TC-71) [3]
Nilotinib + Docetaxel DCS32ZM Nilotinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Nilotinib + Docetaxel DCXMUHT Nilotinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Nilotinib + Docetaxel DCKV56L Nilotinib Astrocytoma (Cell Line: U251) [3]
Nilotinib + Docetaxel DCCLSAT Nilotinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Nilotinib + Docetaxel DC6CCFR Nilotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Nilotinib + Docetaxel DCSR8Y7 Nilotinib Glioblastoma (Cell Line: SNB-75) [3]
Nilotinib + Docetaxel DCNEJFP Nilotinib Glioma (Cell Line: SF-539) [3]
Nilotinib + Docetaxel DC8OL8L Nilotinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Nilotinib + Docetaxel DCA4F17 Nilotinib Renal cell carcinoma (Cell Line: SN12C) [3]
Nilotinib + Docetaxel DCGLBEH Nilotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Nilotinib + Docetaxel DC4E0SY Nilotinib Carcinoma (Cell Line: RXF 393) [4]
Nilotinib + Docetaxel DCMYJ6C Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Nilotinib + Docetaxel DCIFWPD Nilotinib Colon carcinoma (Cell Line: KM12) [4]
Nilotinib + Docetaxel DCBR5KJ Nilotinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Nilotinib + Docetaxel DCSWMPB Nilotinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Nilotinib + Docetaxel DCU6N17 Nilotinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Nilotinib + Docetaxel DCJFVHB Nilotinib Adenocarcinoma (Cell Line: DU-145) [5]
Nilotinib + Docetaxel DC9MJYC Nilotinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Nilotinib + Docetaxel DC5I6IX Nilotinib Adenocarcinoma (Cell Line: A549) [5]
Nilotinib + Docetaxel DC4CLFV Nilotinib Adenocarcinoma (Cell Line: NCIH23) [5]
Nilotinib + Docetaxel DC49H1J Nilotinib Adenocarcinoma (Cell Line: HT29) [5]
Nilotinib + Docetaxel DCGCCIV Nilotinib Adenocarcinoma (Cell Line: HCT116) [5]
Nilotinib + Docetaxel DCQYB7D Nilotinib Adenocarcinoma (Cell Line: HCC-2998) [5]
Nilotinib + Docetaxel DCF4TR1 Nilotinib Adenocarcinoma (Cell Line: SW-620) [5]
Nilotinib + Docetaxel DCZX362 Nilotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Nilotinib + Docetaxel DCSES00 Nilotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Nilotinib + Docetaxel DCT273K Nilotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Nilotinib + Docetaxel DCQH9HD Nilotinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Nilotinib + Docetaxel DC24U1V Nilotinib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Nilotinib + Docetaxel DCBR0AQ Nilotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Nilotinib + Docetaxel DCLAANY Nilotinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Nitrosoglutathione + Docetaxel DCQ9K8G Nitrosoglutathione Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Novobiocin + Docetaxel DC5S6OY Novobiocin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Olmesartan medoxomil + Docetaxel DC3X9DW Olmesartan medoxomil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Omacetaxine mepesuccinate + Docetaxel DCJOJ2E Omacetaxine mepesuccinate DD2 (Cell Line: DD2) [3]
Oxandrolone + Docetaxel DC0ZCZC Oxandrolone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Panobinostat + Docetaxel DCZ88FT Panobinostat Ewing sarcoma (Cell Line: TC-71) [3]
Pazopanib + Docetaxel DCTJBDZ Pazopanib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pazopanib HCl + Docetaxel DC0933B Pazopanib HCl Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pentamidine + Docetaxel DC1JP9M Pentamidine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
PF-02545920 + Docetaxel DCOCYLV PF-02545920 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Picoplatin + Docetaxel DC9MCRQ Picoplatin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pomalidomide + Docetaxel DCODMVR Pomalidomide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pramipexole + Docetaxel DC6BSUC Pramipexole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Probenecid + Docetaxel DCZ0Q0V Probenecid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Procarbazine + Docetaxel DCUKVG5 Procarbazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pyrazinamide + Docetaxel DC90UH0 Pyrazinamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Raloxifene + Docetaxel DCNQHIQ Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Raloxifene + Docetaxel DCTK32V Raloxifene Astrocytoma (Cell Line: U251) [3]
Raloxifene + Docetaxel DC4K947 Raloxifene Lung adenocarcinoma (Cell Line: EKVX) [5]
Repaglinide + Docetaxel DCHK4Y6 Repaglinide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Rifampin + Docetaxel DC6OI9W Rifampin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Ritonavir + Docetaxel DC0G7CG Ritonavir DD2 (Cell Line: DD2) [3]
Romidepsin + Docetaxel DCFPW0H Romidepsin Ewing sarcoma (Cell Line: TC-71) [3]
Ruxolitinib + Docetaxel DCCJ9LQ Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Ruxolitinib + Docetaxel DCWV2GP Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Ruxolitinib + Docetaxel DCH8LKG Ruxolitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Ruxolitinib + Docetaxel DCG229J Ruxolitinib Carcinoma (Cell Line: RXF 393) [4]
Ruxolitinib + Docetaxel DC1LQYC Ruxolitinib Carcinoma (Cell Line: MCF7) [4]
Ruxolitinib + Docetaxel DCBTCDR Ruxolitinib Colon carcinoma (Cell Line: KM12) [4]
Ruxolitinib + Docetaxel DC0TT5Q Ruxolitinib Adenocarcinoma (Cell Line: NCIH23) [5]
Ruxolitinib + Docetaxel DCYV93J Ruxolitinib Adenocarcinoma (Cell Line: SW-620) [5]
Ruxolitinib + Docetaxel DCWGPHR Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Ruxolitinib + Docetaxel DCOT03C Ruxolitinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Ruxolitinib + Docetaxel DCX3SEH Ruxolitinib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Ruxolitinib + Docetaxel DCKHUR2 Ruxolitinib Malignant melanoma (Cell Line: LOX IMVI) [5]
Ruxolitinib + Docetaxel DCNUXYZ Ruxolitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
SCH 727965 + Docetaxel DCIVDY9 SCH 727965 Ewing sarcoma (Cell Line: TC-71) [3]
SCH-900776 + Docetaxel DCOC4E4 SCH-900776 Ewing sarcoma (Cell Line: TC-71) [3]
Sirolimus + Docetaxel DCWA53B Sirolimus Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Sirolimus + Docetaxel DCJSDSY Sirolimus Astrocytoma (Cell Line: U251) [3]
Sirolimus + Docetaxel DCBSFSP Sirolimus Chronic myelogenous leukemia (Cell Line: K-562) [3]
Sirolimus + Docetaxel DCXKPNV Sirolimus Clear cell renal cell carcinoma (Cell Line: A498) [3]
Sirolimus + Docetaxel DCYYZIW Sirolimus Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Sirolimus + Docetaxel DC1PSUA Sirolimus Colon adenocarcinoma (Cell Line: COLO 205) [4]
Sirolimus + Docetaxel DCF70NK Sirolimus Colon carcinoma (Cell Line: KM12) [4]
Sirolimus + Docetaxel DCBTY2J Sirolimus Invasive ductal carcinoma (Cell Line: T-47D) [4]
Sirolimus + Docetaxel DCOW7RM Sirolimus Adenocarcinoma (Cell Line: DU-145) [5]
Sirolimus + Docetaxel DCLK7PY Sirolimus Adenocarcinoma (Cell Line: OVCAR3) [5]
Sirolimus + Docetaxel DCY02V0 Sirolimus Adenocarcinoma (Cell Line: A549) [5]
Sirolimus + Docetaxel DC8ZNH5 Sirolimus Adenocarcinoma (Cell Line: HT29) [5]
Sirolimus + Docetaxel DC845ZU Sirolimus Adenocarcinoma (Cell Line: HCT116) [5]
Sirolimus + Docetaxel DCMZYRP Sirolimus Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Sirolimus + Docetaxel DCW5LD9 Sirolimus Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Sirolimus + Docetaxel DC6ZYWG Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Sirolimus + Docetaxel DCHFDIF Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Sirolimus + Docetaxel DCZGZWG Sirolimus Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Sirolimus + Docetaxel DCZ986H Sirolimus Malignant melanoma (Cell Line: UACC62) [5]
Sirolimus + Docetaxel DCEZJCM Sirolimus Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Sirolimus + Docetaxel DCQ0IS4 Sirolimus Prostate carcinoma (Cell Line: PC-3) [5]
SNX-5422 + Docetaxel DCSRM9I SNX-5422 Ewing sarcoma (Cell Line: TC-71) [3]
Sorafenib + Docetaxel DCRB4S1 Sorafenib DD2 (Cell Line: DD2) [3]
Spironolactone + Docetaxel DCN9JIH Spironolactone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sumatriptan + Docetaxel DC878AZ Sumatriptan Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
SY-1425 + Docetaxel DC97CPL SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
SY-1425 + Docetaxel DCS4I3S SY-1425 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
SY-1425 + Docetaxel DCABU9S SY-1425 Anaplastic large cell lymphoma (Cell Line: SR) [3]
SY-1425 + Docetaxel DC4ODWE SY-1425 Astrocytoma (Cell Line: U251) [3]
SY-1425 + Docetaxel DCKKJVP SY-1425 Astrocytoma (Cell Line: SNB-19) [3]
SY-1425 + Docetaxel DC9JMBK SY-1425 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
SY-1425 + Docetaxel DC5FDQ7 SY-1425 Chronic myelogenous leukemia (Cell Line: K-562) [3]
SY-1425 + Docetaxel DCA2NMN SY-1425 Clear cell renal cell carcinoma (Cell Line: A498) [3]
SY-1425 + Docetaxel DCG1TG7 SY-1425 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
SY-1425 + Docetaxel DC6LL9E SY-1425 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
SY-1425 + Docetaxel DCTEX0N SY-1425 Glioblastoma (Cell Line: SNB-75) [3]
SY-1425 + Docetaxel DCWFJ67 SY-1425 Glioma (Cell Line: SF-268) [3]
SY-1425 + Docetaxel DCJ4UFM SY-1425 Glioma (Cell Line: SF-295) [3]
SY-1425 + Docetaxel DCIEM4V SY-1425 Glioma (Cell Line: SF-539) [3]
SY-1425 + Docetaxel DC1F8HA SY-1425 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
SY-1425 + Docetaxel DCG235K SY-1425 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
SY-1425 + Docetaxel DCUKN23 SY-1425 Renal cell carcinoma (Cell Line: UO-31) [3]
SY-1425 + Docetaxel DC3LJXB SY-1425 Renal cell carcinoma (Cell Line: SN12C) [3]
SY-1425 + Docetaxel DC6Y8EZ SY-1425 Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
SY-1425 + Docetaxel DCEY78C SY-1425 Carcinoma (Cell Line: RXF 393) [4]
SY-1425 + Docetaxel DCVPKK3 SY-1425 Colon adenocarcinoma (Cell Line: COLO 205) [4]
SY-1425 + Docetaxel DC9GUBY SY-1425 Colon carcinoma (Cell Line: KM12) [4]
SY-1425 + Docetaxel DCLEGSI SY-1425 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
SY-1425 + Docetaxel DCSOMJB SY-1425 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SY-1425 + Docetaxel DC23Z7Y SY-1425 Invasive ductal carcinoma (Cell Line: BT-549) [4]
SY-1425 + Docetaxel DCJ12EK SY-1425 Adenocarcinoma (Cell Line: DU-145) [5]
SY-1425 + Docetaxel DCC2YML SY-1425 Adenocarcinoma (Cell Line: OVCAR3) [5]
SY-1425 + Docetaxel DCHYXGA SY-1425 Adenocarcinoma (Cell Line: NCIH23) [5]
SY-1425 + Docetaxel DC52BTU SY-1425 Adenocarcinoma (Cell Line: A549) [5]
SY-1425 + Docetaxel DCJYFB2 SY-1425 Adenocarcinoma (Cell Line: HCT116) [5]
SY-1425 + Docetaxel DCHC3PZ SY-1425 Adenocarcinoma (Cell Line: SW-620) [5]
SY-1425 + Docetaxel DCQK6JZ SY-1425 Adenocarcinoma (Cell Line: HT29) [5]
SY-1425 + Docetaxel DCKU98Z SY-1425 Adenocarcinoma (Cell Line: HCC-2998) [5]
SY-1425 + Docetaxel DCR78CI SY-1425 Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
SY-1425 + Docetaxel DCOF830 SY-1425 Amelanotic melanoma (Cell Line: M14) [5]
SY-1425 + Docetaxel DCAH8VO SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
SY-1425 + Docetaxel DCE1G93 SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
SY-1425 + Docetaxel DCKMF5J SY-1425 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
SY-1425 + Docetaxel DCNMOSH SY-1425 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
SY-1425 + Docetaxel DCGMGB5 SY-1425 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
SY-1425 + Docetaxel DC4MXNY SY-1425 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
SY-1425 + Docetaxel DCYNU9Q SY-1425 Lung adenocarcinoma (Cell Line: EKVX) [5]
SY-1425 + Docetaxel DCAAULM SY-1425 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
SY-1425 + Docetaxel DCF5W8G SY-1425 Lung adenocarcinoma (Cell Line: NCI-H522) [5]
SY-1425 + Docetaxel DCOOYOU SY-1425 Malignant melanoma (Cell Line: UACC62) [5]
SY-1425 + Docetaxel DC6ZQYH SY-1425 Melanoma (Cell Line: MALME-3M) [5]
SY-1425 + Docetaxel DCUN3GK SY-1425 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
SY-1425 + Docetaxel DC5XVFL SY-1425 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
SY-1425 + Docetaxel DCMQZOQ SY-1425 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
SY-1425 + Docetaxel DCPK13U SY-1425 Prostate carcinoma (Cell Line: PC-3) [5]
Tacrolimus + Docetaxel DCHFDN8 Tacrolimus Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Taxol + Docetaxel DC5HIC8 Taxol Astrocytoma (Cell Line: U251) [3]
Taxol + Docetaxel DCJ3IQ2 Taxol Colon adenocarcinoma (Cell Line: COLO 205) [4]
Taxol + Docetaxel DC8FT6I Taxol Adenocarcinoma (Cell Line: DU-145) [5]
Taxol + Docetaxel DCU1V9T Taxol Prostate carcinoma (Cell Line: PC-3) [5]
Testolactone + Docetaxel DCXO70E Testolactone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
THAPSIGARGIN + Docetaxel DCXQ8IS THAPSIGARGIN Ewing sarcoma (Cell Line: TC-71) [3]
Tolazoline + Docetaxel DCRA42A Tolazoline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Tolvaptan + Docetaxel DC99HJS Tolvaptan Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Topotecan + Docetaxel DCHRY14 Topotecan Melanoma (Cell Line: MALME-3M) [5]
Topotecan + Docetaxel DCCB7RC Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Topotecan + Docetaxel DCSYJLS Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Triamterene + Docetaxel DC7UQDR Triamterene Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Triflupromazine + Docetaxel DC3EKU5 Triflupromazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Trifluridine + Docetaxel DCTS7ZO Trifluridine Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Trifluridine + Docetaxel DC8OY5Q Trifluridine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Trifluridine + Docetaxel DCC6KO4 Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Trimethobenzamide + Docetaxel DCCOLX1 Trimethobenzamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Tropisetron + Docetaxel DC9MG75 Tropisetron Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Uracil mustard + Docetaxel DCL68E1 Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Valrubicin + Docetaxel DC3TLTL Valrubicin Astrocytoma (Cell Line: U251) [3]
Valrubicin + Docetaxel DC5YD22 Valrubicin Astrocytoma (Cell Line: SNB-19) [3]
Valrubicin + Docetaxel DCFI7YN Valrubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Valrubicin + Docetaxel DC6P828 Valrubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Valrubicin + Docetaxel DCGES92 Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Valrubicin + Docetaxel DCZVILY Valrubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Valrubicin + Docetaxel DC7DHCD Valrubicin Glioma (Cell Line: SF-268) [3]
Valrubicin + Docetaxel DCEVP90 Valrubicin Renal cell carcinoma (Cell Line: UO-31) [3]
Valrubicin + Docetaxel DC1T0V2 Valrubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Valrubicin + Docetaxel DC4GFQ0 Valrubicin Carcinoma (Cell Line: RXF 393) [4]
Valrubicin + Docetaxel DCQ5SSA Valrubicin Carcinoma (Cell Line: MCF7) [4]
Valrubicin + Docetaxel DCRVRX4 Valrubicin Colon carcinoma (Cell Line: KM12) [4]
Valrubicin + Docetaxel DCNY2DY Valrubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Valrubicin + Docetaxel DC89KJB Valrubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Valrubicin + Docetaxel DCS3D6C Valrubicin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Valrubicin + Docetaxel DCWQV1B Valrubicin Adenocarcinoma (Cell Line: DU-145) [5]
Valrubicin + Docetaxel DCN7UQ5 Valrubicin Adenocarcinoma (Cell Line: A549) [5]
Valrubicin + Docetaxel DC1EW9E Valrubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Valrubicin + Docetaxel DCVGAQS Valrubicin Adenocarcinoma (Cell Line: SW-620) [5]
Valrubicin + Docetaxel DCG5QWK Valrubicin Adenocarcinoma (Cell Line: HCT116) [5]
Valrubicin + Docetaxel DCYTFLY Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Valrubicin + Docetaxel DCSLWUS Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Valrubicin + Docetaxel DCWKNLO Valrubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Valrubicin + Docetaxel DCNO35O Valrubicin Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Valrubicin + Docetaxel DCHONCJ Valrubicin Malignant melanoma (Cell Line: LOX IMVI) [5]
Valrubicin + Docetaxel DCSV7GE Valrubicin Malignant melanoma (Cell Line: UACC62) [5]
Valrubicin + Docetaxel DCGWB2J Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Valrubicin + Docetaxel DCF9D8Y Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Valrubicin + Docetaxel DC5WFCN Valrubicin Prostate carcinoma (Cell Line: PC-3) [5]
Vandetanib + Docetaxel DC0J7WF Vandetanib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vandetanib + Docetaxel DCC4M9B Vandetanib Carcinoma (Cell Line: RXF 393) [4]
Vandetanib + Docetaxel DC2M5NV Vandetanib Adenocarcinoma (Cell Line: A549) [5]
Vandetanib + Docetaxel DC6G4IM Vandetanib Adenocarcinoma (Cell Line: NCIH23) [5]
Vandetanib + Docetaxel DCBEPWP Vandetanib Adenocarcinoma (Cell Line: SW-620) [5]
Vandetanib + Docetaxel DCZZ3FG Vandetanib Adenocarcinoma (Cell Line: HCT-15) [5]
Vandetanib + Docetaxel DCG6T53 Vandetanib Adenocarcinoma (Cell Line: HCC-2998) [5]
Vandetanib + Docetaxel DC9L3NY Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vandetanib + Docetaxel DC7QY1Z Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vandetanib + Docetaxel DCW7LVJ Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vandetanib + Docetaxel DCWFT5F Vandetanib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vandetanib + Docetaxel DCY7M26 Vandetanib Malignant melanoma (Cell Line: LOX IMVI) [5]
Vandetanib + Docetaxel DC9PBT3 Vandetanib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vandetanib + Docetaxel DCM6K3Y Vandetanib Prostate carcinoma (Cell Line: PC-3) [5]
Vandetanib + Docetaxel DCPLE49 Vandetanib Renal cell carcinoma (Cell Line: SN12C) [5]
Vemurafenib + Docetaxel DCVGNLV Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vemurafenib + Docetaxel DCFNP6S Vemurafenib Carcinoma (Cell Line: RXF 393) [4]
Vemurafenib + Docetaxel DCW1E81 Vemurafenib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vemurafenib + Docetaxel DCGH6TV Vemurafenib Adenocarcinoma (Cell Line: HT29) [5]
Vemurafenib + Docetaxel DCJG8TE Vemurafenib Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vemurafenib + Docetaxel DCLPGLM Vemurafenib Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vemurafenib + Docetaxel DCYZA87 Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vemurafenib + Docetaxel DC4O27L Vemurafenib Malignant melanoma (Cell Line: UACC62) [5]
Vemurafenib + Docetaxel DC1AQE5 Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [5]
Vemurafenib + Docetaxel DCXTZCI Vemurafenib Melanoma (Cell Line: UACC-257) [5]
Vemurafenib + Docetaxel DCMNEM6 Vemurafenib Melanoma (Cell Line: MALME-3M) [5]
Vemurafenib + Docetaxel DC0OBFN Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vemurafenib + Docetaxel DC2SQTT Vemurafenib Renal cell carcinoma (Cell Line: UO-31) [5]
Verteporfin + Docetaxel DCRNHBC Verteporfin Ewing sarcoma (Cell Line: TC-71) [3]
Vincristine + Docetaxel DCJ8PRV Vincristine Adenocarcinoma (Cell Line: DU-145) [3]
Vincristine + Docetaxel DCLQ2VV Vincristine Clear cell renal cell carcinoma (Cell Line: A498) [3]
Vincristine + Docetaxel DCNUIL6 Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Vinflunine + Docetaxel DC97B6D Vinflunine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Vinflunine + Docetaxel DCID2BG Vinflunine Astrocytoma (Cell Line: U251) [3]
Vinflunine + Docetaxel DCC4ZAE Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Vinflunine + Docetaxel DCZ2GJO Vinflunine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Vinflunine + Docetaxel DCLQTCZ Vinflunine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vinflunine + Docetaxel DC3J9KR Vinflunine Adenocarcinoma (Cell Line: HT29) [5]
Vinflunine + Docetaxel DCG8R6X Vinflunine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vinflunine + Docetaxel DCIMFCX Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Vinflunine + Docetaxel DCZJUZ6 Vinflunine Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Docetaxel DCQLNHT Vismodegib Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Docetaxel DCLQKAB Vismodegib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Docetaxel DC8ICGX Vismodegib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Docetaxel DCQ8GKZ Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Docetaxel DCSVJLJ Vismodegib Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Docetaxel DCVXYA5 Vismodegib Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Docetaxel DCOZX1J Vismodegib Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Docetaxel DCGY4EW Vismodegib Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Docetaxel DC66ILA Vismodegib Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Docetaxel DCZNE4U Vismodegib Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Docetaxel DCHW6JM Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Docetaxel DCYH90M Vismodegib Astrocytoma (Cell Line: U251) [5]
Vismodegib + Docetaxel DCTLK1F Vismodegib Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Docetaxel DCXL8JF Vismodegib Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Docetaxel DCA6VWG Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Docetaxel DCFZZ3B Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Docetaxel DCIR1ED Vismodegib Glioma (Cell Line: SF-539) [5]
Vismodegib + Docetaxel DCOUPO7 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Docetaxel DCHQU3I Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Docetaxel DC4C60X Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Docetaxel DCFWCQC Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Docetaxel DCAABUO Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Docetaxel DCXUWHF Vismodegib Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Docetaxel DCFXJ95 Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Docetaxel DCKE3OM Vismodegib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Docetaxel DCA98VS Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Docetaxel DC12WV4 Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Docetaxel DC5JCM4 Vismodegib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Docetaxel DCIAZA2 Vismodegib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Docetaxel DCDNVZ2 Vismodegib Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Docetaxel DCJ5J1W Vismodegib Renal cell carcinoma (Cell Line: SN12C) [5]
Vorinostat + Docetaxel DCNZETV Vorinostat Hepatoblastoma (Cell Line: HB3) [3]
WAY-100635 + Docetaxel DCD2CJU WAY-100635 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
ZM-447439 + Docetaxel DCFA09Q ZM-447439 DD2 (Cell Line: DD2) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1124 DrugCom(s)
152 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Al3818 + Docetaxel DCI5JZH Al3818 Non-squamous Non-small Cell Lung Cancer [6]
Buparlisib + Docetaxel DCBVG9K Buparlisib Squamous Non-small Cell Lung Cancer [7]
Celecoxib + Docetaxel DC8T0AQ Celecoxib Lung Cancer [8]
Ceritinib + Docetaxel DCSDTVC Ceritinib Non-small Cell Lung Cancer [9]
Clarithromycin + Docetaxel DC0ZW7Z Clarithromycin Prostate Cancer [10]
Cyclophosphamide + Docetaxel DCATK50 Cyclophosphamide Breast Cancer [11]
Cyclophosphamide + Docetaxel DCU9D0Y Cyclophosphamide Breast Cancer [11]
Cyclophosphamide + Docetaxel DCD72UI Cyclophosphamide Breast Cancer [12]
Cyclophosphamide + Docetaxel DCO7SQF Cyclophosphamide Neutropenia [13]
Dexamethasone + Docetaxel DCAYJBW Dexamethasone Bladder Cancer [14]
Docetaxel + Pazopanib DC6DYV3 Pazopanib Neoplasms, Breast [15]
Docetaxel + Oxaliplatin DCXQDVZ Oxaliplatin Esophagus Cancer [16]
Docetaxel + Flavopiridol DC0KSVQ Flavopiridol Adenocarcinoma of the Pancreas [17]
Docetaxel + Carboplatin DC15B1A Carboplatin Ovarian Cancer [18]
Docetaxel + Zibotentan DC18SUA Zibotentan Prostate Cancer [19]
Docetaxel + CATECHIN DC1DKCA CATECHIN Breast Cancer [20]
Docetaxel + Dasatinib DC27E5H Dasatinib Metastatic Prostate Cancer [21]
Docetaxel + Pemetrexed DC4YXHW Pemetrexed Breast Cancer [22]
Docetaxel + Irinotecan DC53GGM Irinotecan Lung Cancer [23]
Docetaxel + Custirsen DC68PRA Custirsen Non-Small Cell Lung Cancer [24]
Docetaxel + Pemetrexed DC7M6MW Pemetrexed Lung Cancer [25]
Docetaxel + Perifosine DC7OT9R Perifosine Ovarian Cancer [26]
Docetaxel + PX-866 DC7YMDW PX-866 Non Small Cell Lung Cancer (NSCLC) [27]
Docetaxel + Irinotecan DC83PVM Irinotecan Esophageal Cancer [28]
Docetaxel + Bortezomib DC8AWAI Bortezomib Lung Cancer [29]
Docetaxel + Vandetanib DCB58HH Vandetanib Non-small Cell Lung Cancer [30]
Docetaxel + Ketoconazole DCBH0CB Ketoconazole Solid Tumors [31]
Docetaxel + Pemetrexed DCBWDP3 Pemetrexed Non Small Cell Lung Cancer [32]
Docetaxel + Capecitabine DCCWXZ6 Capecitabine Breast Cancer [33]
Docetaxel + Tanespimycin DCDGRBZ Tanespimycin Recurrent Prostate Cancer [34]
Docetaxel + Pazopanib DCE8F5T Pazopanib Neoplasms, Breast [15]
Docetaxel + Afatinib DCENAN5 Afatinib Neoplasms [35]
Docetaxel + Prednisone DCH4ST3 Prednisone Prostate Cancer [36]
Docetaxel + [125I]IRL1620 DCHAMMC [125I]IRL1620 Non Small Cell Lung Cancer (NSCLC) [37]
Docetaxel + Imatinib DCHH8U7 Imatinib Breast Cancer [38]
Docetaxel + Suramin DCITVH0 Suramin Recurrent Non-small Cell Lung Cancer [39]
Docetaxel + Enzalutamide DCJ5U1O Enzalutamide Metastatic Castration Resistant Prostate Cancer [40]
Docetaxel + Oxaliplatin DCJLKL8 Oxaliplatin Esophagus Cancer [16]
Docetaxel + Vorinostat DCKGEJR Vorinostat Non-Small-Cell Lung Carcinoma [41]
Docetaxel + Imatinib DCKT7LL Imatinib Metastatic Cancer [42]
Docetaxel + Aflibercept DCL2NZG Aflibercept Neoplasms [43]
Docetaxel + Lonafarnib DCL9287 Lonafarnib Lung Cancer [44]
Docetaxel + VATALANIB DCL9UFM VATALANIB Ovarian Cancer [45]
Docetaxel + Capecitabine DCLDWI8 Capecitabine Esophageal Cancer [46]
Docetaxel + Nintedanib DCLJ9PR Nintedanib Breast Cancer [47]
Docetaxel + Estramustine DCN6FU5 Estramustine Prostate Cancer [48]
Docetaxel + Perifosine DCOCHZX Perifosine Neoplasms [49]
Docetaxel + Aflibercept DCP7BKB Aflibercept Neoplasm Malignant [50]
Docetaxel + Hydroxychloroquine DCPKO3J Hydroxychloroquine Prostate Cancer [51]
Docetaxel + Tariquidar DCPW53G Tariquidar Lung Neoplasms [52]
Docetaxel + Epirubicin DCR7L6G Epirubicin Breast Cancer [53]
Docetaxel + Temsirolimus DCSMSTV Temsirolimus Resistant Solid Malignancies [54]
Docetaxel + MLN8237 DCSS5OL MLN8237 Advanced Solid Tumors [55]
Docetaxel + Vandetanib DCSTJFP Vandetanib Advanced Breast Cancer [56]
Docetaxel + Tasisulam DCT6QOI Tasisulam Advanced Solid Tumors [57]
Docetaxel + Axitinib DCTHBM7 Axitinib Breast Neoplasms [58]
Docetaxel + Vinorelbine DCTHM2N Vinorelbine Lung Cancer [59]
Docetaxel + Bortezomib DCUJT3P Bortezomib Adenocarcinoma of the Lung [60]
Docetaxel + Mitoxantrone DCVRZZ6 Mitoxantrone Prostate Cancer [61]
Docetaxel + Modafinil DCVU12W Modafinil Prostatic Neoplasms [62]
Docetaxel + Vinorelbine DCW95ZL Vinorelbine Breast Cancer [63]
Docetaxel + Oxaliplatin DCXFBXW Oxaliplatin Esophageal Cancer [64]
Docetaxel + Carboplatin DC5VKGA Carboplatin Brenner Tumor [65]
Docetaxel + Carboplatin DCEYJOS Carboplatin Non Small Cell Lung Cancer [66]
Docetaxel + Oxaliplatin DCY0HZW Oxaliplatin Adenocarcinoma of the Gastroesophageal Junction [67]
Docetaxel + Ibrutinib DCB1H3B Ibrutinib Metastatic Renal Cell Carcinoma [68]
Docetaxel + GDC-0032 DCJFMX0 GDC-0032 Breast Cancer, Non-small Lung Cancer [69]
Docetaxel + LDE225 DCRSET1 LDE225 Advanced Breast Cancer [70]
E7850 + Docetaxel DCOHOB2 E7850 Solid tumour/cancer [71]
Erlotinib + Docetaxel DCDPJ7J Erlotinib Lung Cancer [25]
Erlotinib + Docetaxel DC1W6LW Erlotinib Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma [72]
Erlotinib + Docetaxel DCGAKWQ Erlotinib Recurrent Salivary Gland Cancer [73]
Gefitinib + Docetaxel DCDSSKB Gefitinib Breast Cancer [74]
Gefitinib + Docetaxel DCMPLO1 Gefitinib Non-small Cell Lung Cancer [75]
Gemcitabine + Docetaxel DC2DM1F Gemcitabine Breast Cancer [76]
Gemcitabine + Docetaxel DC0A2KP Gemcitabine Stage III Adult Soft Tissue Sarcoma [77]
Gemcitabine + Docetaxel DCPEA51 Gemcitabine Pancreatic Cancer [78]
Gonadorelin + Docetaxel DCVR00C Gonadorelin Prostate Cancer [79]
Goserelin + Docetaxel DC520FJ Goserelin Prostate Cancer [80]
Lapatinib + Docetaxel DC39K68 Lapatinib Neoplasms, Breast [15]
Lapatinib + Docetaxel DC3OMTZ Lapatinib Neoplasms, Breast [81]
Leuprolide + Docetaxel DCBLK3Y Leuprolide Prostatic Neoplasms [82]
Leuprolide + Docetaxel DC3W6F5 Leuprolide Prostate Cancer [83]
Leuprolide + Docetaxel DCHCJ2P Leuprolide Prostatic Neoplasms [84]
Leuprolide + Docetaxel DCB97BQ Leuprolide Prostate Cancer [85]
Lovastatin + Docetaxel DC23MGG Lovastatin Any Cancer [86]
Nedaplatin + Docetaxel DCQT035 Nedaplatin Esophageal Neoplasms [87]
NLG8189 + Docetaxel DCN59VF NLG8189 Unspecified Adult Solid Tumor, Protocol Specific [88]
NLG8189 + Docetaxel DCDJZEC NLG8189 Non-small Cell Lung Cancer [89]
Ombrabulin + Docetaxel DCO2EW2 Ombrabulin Advanced Neoplastic Disease [90]
PBI-05204 + Docetaxel DCY8YDU PBI-05204 Chemotherapeutic Agent Toxicity [91]
PD-0325901 + Docetaxel DCS8A41 PD-0325901 Colorectal Cancer [92]
PF-05212384 + Docetaxel DCKJ6WF PF-05212384 Neoplasm [93]
Phenoxodiol + Docetaxel DCA0V2H Phenoxodiol Fallopian Tube Cancer [94]
Pralatrexate + Docetaxel DCP5WMB Pralatrexate Adenocarcinoma of the Esophagus [95]
Rivoceranib + Docetaxel DCTW18V Rivoceranib Metastatic Gastric Adenocarcinoma [96]
Savolitinib + Docetaxel DCZ3Q5H Savolitinib Gastric Cancer [97]
Selinexor + Docetaxel DCBLXMC Selinexor Non-small Cell Lung Cancer [98]
Selinexor + Docetaxel DCLMORP Selinexor Non-Small Cell Lung Carcinoma (NSCLC) [99]
Selumetinib + Docetaxel DCHWLP8 Selumetinib Breast Cancer [100]
Selumetinib + Docetaxel DCYMK8K Selumetinib Non Small Cell Lung Cancer [101]
Sunitinib + Docetaxel DCDEV8F Sunitinib Prostate Cancer [102]
Sunitinib + Docetaxel DCPKS2E Sunitinib Advanced Solid Tumors [103]
Tegafur + Docetaxel DC6WSTH Tegafur Gastric Cancer [104]
Trametinib + Docetaxel DCWYV9Y Trametinib Cancer [105]
Celecoxib + Docetaxel DC5PGB5 Celecoxib Lung Cancer [106]
Degarelix + Docetaxel DCRLEVT Degarelix Metastatic Prostatic Adenocarcinoma [107]
Dexamethasone + Docetaxel DC0DQFL Dexamethasone Nasopharyngeal Carcinoma [108]
Docetaxel + Docetaxel DC775W1 Docetaxel High-grade Serous Ovarian Carcinoma [109]
Docetaxel + Zoledronate DCI3EHU Zoledronate Hormone-Refractory Prostate Cancer [110]
Docetaxel + Oxaliplatin DCU1KY6 Oxaliplatin Gastric Cancer [111]
Docetaxel + Oxaliplatin DCZA6J2 Oxaliplatin Gastric Cancer [112]
Docetaxel + Enzalutamide DCMSCEH Enzalutamide Metastatic Castration-Resistant Prostate Cancer (mCRPC) [113]
Docetaxel + Epirubicin DCR841C Epirubicin Breast Neoplasms [114]
Docetaxel + Cabazitaxel DCS38PC Cabazitaxel Prostate Carcinoma [115]
Docetaxel + Silibinin DCVPMM8 Silibinin Upper GI Cancer [116]
Duvelisib + Docetaxel DCA97LH Duvelisib Squamous Cell Carcinoma of the Head and Neck (SCCHN) [117]
Erlotinib + Docetaxel DC0K3P2 Erlotinib Non Small Cell Lung Cancer [118]
Floxuridine + Docetaxel DC69W1Q Floxuridine Gastric Cancer [119]
Floxuridine + Docetaxel DCJV4WA Floxuridine Esophageal Cancer [120]
Fulvestrant + Docetaxel DCGHK79 Fulvestrant Metastatic Breast Cancer [121]
Gemcitabine + Docetaxel DC38QMC Gemcitabine Carcinoma, Non-Small-Cell Lung [122]
Gemcitabine + Docetaxel DC4EPQ1 Gemcitabine Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [123]
Gemcitabine + Docetaxel DC79PW1 Gemcitabine Pancreatic Cancer [124]
Gemcitabine + Docetaxel DCC81JT Gemcitabine Non-small Cell Lung Cancer [125]
Gemcitabine + Docetaxel DCKBNU3 Gemcitabine Breast Cancer [126]
Gemcitabine + Docetaxel DCZ6U23 Gemcitabine Lung Cancer [127]
INCB039110 + Docetaxel DCG0YZE INCB039110 NSCLC (Non-small Cell Lung Carcinoma) [128]
Leuprolide + Docetaxel DCUVPRW Leuprolide Prostate Cancer [129]
MK-1775 + Docetaxel DCD4BKP MK-1775 Lung Cancer [130]
Rivoceranib + Docetaxel DCSW81G Rivoceranib Gastric Cancer [131]
Savolitinib + Docetaxel DCG4HDO Savolitinib Advanced Gastric Adenocarcinoma [132]
Selegiline + Docetaxel DCX5JW7 Selegiline Metastatic Castration-resistant Prostate Cancer [133]
Tegafur + Docetaxel DCVK88R Tegafur Gastric Cancer [134]
ABIRATERONE + Docetaxel DCDPHIL ABIRATERONE Metastatic Prostate Cancer [135]
Cyclophosphamide + Docetaxel DCSD3XA Cyclophosphamide Breast Cancer [136]
Dexamethasone + Docetaxel DC72QL1 Dexamethasone Carcinoma [137]
Docetaxel + Epirubicin DC11HNK Epirubicin Breast Cancer [138]
Docetaxel + Carboplatin DC4CO7S Carboplatin Non-small Cell Lung Cancer [139]
Docetaxel + Docetaxel DC57S8S Docetaxel Esophageal Carcinoma [140]
Docetaxel + Paclitaxel DC8P2TD Paclitaxel Locally Advanced or Metastatic Unresectable Urothelial Cancer [141]
Docetaxel + Enzalutamide DCFMABY Enzalutamide Metastatic Castration Resistant Prostate Cancer [142]
Docetaxel + Nintedanib DC2J3QA Nintedanib Carcinoma, Non-Small-Cell Lung [143]
Docetaxel + Daunorubicin DCCIJAA Daunorubicin Endometrial Neoplasms [144]
Docetaxel + Vinflunine DCP3FIP Vinflunine Urothelial Cancer [145]
Erlotinib + Docetaxel DCCQEC5 Erlotinib Non-Squamous Non-Small Cell Lung Cancer [146]
Gemcitabine + Docetaxel DC7IH5M Gemcitabine Advanced Non-Small Cell Lung Cancer [147]
Gemcitabine + Docetaxel DC7N6IM Gemcitabine Nasopharyngeal Neoplasms [148]
Methotrexate + Docetaxel DCQK0OU Methotrexate Head and Neck Squamous Cell Cancer [149]
Olaparib + Docetaxel DCXC47B Olaparib Ovarian Cancer [150]
Docetaxel + Epirubicin DCSZAA6 Epirubicin Breast Cancer [151]
Nedaplatin + Docetaxel DCFVD5H Nedaplatin Squamous Cell Carcinoma [152]
------------------------------------------------------------------------------------
⏷ Show the Full List of 152 DrugCom(s)

References

1 Docetaxel FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT03566576) Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
7 ClinicalTrials.gov (NCT01911325) Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
8 ClinicalTrials.gov (NCT00030407) Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
9 ClinicalTrials.gov (NCT03611738) Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
10 ClinicalTrials.gov (NCT03043989) Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
11 ClinicalTrials.gov (NCT00432172) Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
12 ClinicalTrials.gov (NCT00493870) TAC Versus TC for Adjuvant Breast Cancer
13 ClinicalTrials.gov (NCT04187898) Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
14 ClinicalTrials.gov (NCT00479089) Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
15 ClinicalTrials.gov (NCT00388076) Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
16 ClinicalTrials.gov (NCT00193128) Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
17 ClinicalTrials.gov (NCT00331682) Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
18 ClinicalTrials.gov (NCT00090610) Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
19 ClinicalTrials.gov (NCT00314782) Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
20 ClinicalTrials.gov (NCT00887536) A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
21 ClinicalTrials.gov (NCT00439270) Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
22 ClinicalTrials.gov (NCT01172028) Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
23 ClinicalTrials.gov (NCT00003900) Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
24 ClinicalTrials.gov (NCT01630733) A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
25 ClinicalTrials.gov (NCT00660816) Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
26 ClinicalTrials.gov (NCT00431054) Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
27 ClinicalTrials.gov (NCT01204099) Study of PX-866 and Docetaxel in Solid Tumors
28 ClinicalTrials.gov (NCT00004235) Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
29 ClinicalTrials.gov (NCT00064012) Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
30 ClinicalTrials.gov (NCT00312377) ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
31 ClinicalTrials.gov (NCT00697437) Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel
32 ClinicalTrials.gov (NCT00684099) Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)
33 ClinicalTrials.gov (NCT00050167) Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
34 ClinicalTrials.gov (NCT00058253) Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
35 ClinicalTrials.gov (NCT01251653) A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
36 ClinicalTrials.gov (NCT00598858) Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate
37 ClinicalTrials.gov (NCT01741155) Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
38 ClinicalTrials.gov (NCT00193180) Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
39 ClinicalTrials.gov (NCT00066768) Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer
40 ClinicalTrials.gov (NCT03328364) A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
41 ClinicalTrials.gov (NCT00565227) Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
42 ClinicalTrials.gov (NCT00084825) Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
43 ClinicalTrials.gov (NCT00545246) A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
44 ClinicalTrials.gov (NCT00288444) Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
45 ClinicalTrials.gov (NCT00268918) Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
46 ClinicalTrials.gov (NCT00054457) Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
47 ClinicalTrials.gov (NCT01658462) Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
48 ClinicalTrials.gov (NCT00004001) S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
49 ClinicalTrials.gov (NCT00399087) Phase I Trial of Docetaxel With Perifosine
50 ClinicalTrials.gov (NCT01148615) A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
51 ClinicalTrials.gov (NCT00786682) Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
52 ClinicalTrials.gov (NCT00069160) Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
53 ClinicalTrials.gov (NCT00424606) Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
54 ClinicalTrials.gov (NCT00703625) Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
55 ClinicalTrials.gov (NCT01094288) A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
56 ClinicalTrials.gov (NCT00494481) E3 Breast Cancer Taxotere Combination
57 ClinicalTrials.gov (NCT01284335) A Safety Study in Participants With Advanced Solid Tumors
58 ClinicalTrials.gov (NCT00076024) AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
59 ClinicalTrials.gov (NCT00736814) First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
60 ClinicalTrials.gov (NCT00118183) Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
61 ClinicalTrials.gov (NCT00017563) Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
62 ClinicalTrials.gov (NCT00917748) Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
63 ClinicalTrials.gov (NCT00015938) S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
64 ClinicalTrials.gov (NCT00217581) Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
65 ClinicalTrials.gov (NCT00085358) Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
66 ClinicalTrials.gov (NCT00714246) Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
67 ClinicalTrials.gov (NCT00732745) Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
68 ClinicalTrials.gov (NCT02599324) Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
69 ClinicalTrials.gov (NCT01862081) A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
70 ClinicalTrials.gov (NCT02027376) Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
71 MGI PHARMA Initiates Drug Combination Trial of Irofulven and Taxotere in Patients With Advanced Cancers; Phase 1 Dose-Escalating Trial to Evaluate Novel Combination Therapy. 2001 Business Wire
72 ClinicalTrials.gov (NCT00049283) Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
73 ClinicalTrials.gov (NCT00055770) Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
74 ClinicalTrials.gov (NCT00086957) Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
75 ClinicalTrials.gov (NCT00048087) Iressa/Docetaxel in Non-Small-Cell Lung Cancer
76 ClinicalTrials.gov (NCT00191152) A Phase III Trial For Patients With Metastatic Breast Cancer
77 ClinicalTrials.gov (NCT01719302) Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
78 ClinicalTrials.gov (NCT00320749) Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
79 ClinicalTrials.gov (NCT01603420) External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
80 ClinicalTrials.gov (NCT00482807) Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
81 ClinicalTrials.gov (NCT00148902) Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
82 ClinicalTrials.gov (NCT00514917) A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
83 ClinicalTrials.gov (NCT00225420) Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
84 ClinicalTrials.gov (NCT00452556) The ELDORADO (Eligard, Docetaxel and Radiotherapy) Study
85 ClinicalTrials.gov (NCT00099086) Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
86 ClinicalTrials.gov (NCT00584012) A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
87 ClinicalTrials.gov (NCT02429622) Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
88 ClinicalTrials.gov (NCT01191216) 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
89 ClinicalTrials.gov (NCT02460367) Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
90 ClinicalTrials.gov (NCT01907685) Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors
91 ClinicalTrials.gov (NCT01562301) Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
92 ClinicalTrials.gov (NCT02039336) Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
93 ClinicalTrials.gov (NCT01920061) A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
94 ClinicalTrials.gov (NCT00303888) Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
95 ClinicalTrials.gov (NCT01129206) Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
96 ClinicalTrials.gov (NCT03071042) A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
97 ClinicalTrials.gov (NCT02252913) A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer
98 ClinicalTrials.gov (NCT03095612) Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
99 ClinicalTrials.gov (NCT04256707) Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
100 ClinicalTrials.gov (NCT00600496) A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
101 ClinicalTrials.gov (NCT00890825) AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
102 ClinicalTrials.gov (NCT00734851) Multimodality Phase II Study in Prostate Cancer
103 ClinicalTrials.gov (NCT00712504) Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
104 ClinicalTrials.gov (NCT03001726) To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.
105 ClinicalTrials.gov (NCT01192165) Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
106 ClinicalTrials.gov (NCT00520845) Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
107 ClinicalTrials.gov (NCT03069937) Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
108 ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health.
109 ClinicalTrials.gov (NCT05446870) Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
110 ClinicalTrials.gov (NCT00151073) Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
111 ClinicalTrials.gov (NCT02725424) Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
112 ClinicalTrials.gov (NCT02931890) Multicentric Randomised Trial for Resectable Gastric Cancer
113 ClinicalTrials.gov (NCT04015622) PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
114 ClinicalTrials.gov (NCT02307227) Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
115 ClinicalTrials.gov (NCT03101046) Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
116 ClinicalTrials.gov (NCT01829178) Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
117 ClinicalTrials.gov (NCT05057247) Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
118 ClinicalTrials.gov (NCT02037997) Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
119 ClinicalTrials.gov (NCT00448682) Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
120 ClinicalTrials.gov (NCT00448760) Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
121 ClinicalTrials.gov (NCT02137083) A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
122 ClinicalTrials.gov (NCT00215930) The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
123 ClinicalTrials.gov (NCT03041181) Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
124 ClinicalTrials.gov (NCT00882310) A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
125 ClinicalTrials.gov (NCT01774578) Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
126 ClinicalTrials.gov (NCT00193050) Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
127 ClinicalTrials.gov (NCT00193427) Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
128 ClinicalTrials.gov (NCT02257619) Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
129 ClinicalTrials.gov (NCT02716974) A Study of Definitive Therapy to Treat Prostate Cancer
130 ClinicalTrials.gov (NCT02513563) AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
131 ClinicalTrials.gov (NCT02596256) Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
132 ClinicalTrials.gov (NCT02447380) Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
133 ClinicalTrials.gov (NCT04586543) Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
134 ClinicalTrials.gov (NCT02623153) Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer
135 ClinicalTrials.gov (NCT01957436) A Phase III Study for Patients With Metastatic Hormone-nave Prostate Cancer
136 ClinicalTrials.gov (NCT00129935) EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
137 ClinicalTrials.gov (NCT00532155) A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
138 ClinicalTrials.gov (NCT00540800) BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
139 ClinicalTrials.gov (NCT03850444) Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
140 ClinicalTrials.gov (NCT03933449) Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
141 ClinicalTrials.gov (NCT04527991) Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer
142 ClinicalTrials.gov (NCT02288247) A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
143 ClinicalTrials.gov (NCT02231164) LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
144 ClinicalTrials.gov (NCT03517449) Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
145 ClinicalTrials.gov (NCT03390504) A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
146 ClinicalTrials.gov (NCT01351415) A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
147 ClinicalTrials.gov (NCT00345059) The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
148 ClinicalTrials.gov (NCT02611960) Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
149 ClinicalTrials.gov (NCT02252042) Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
150 ClinicalTrials.gov (NCT03740165) Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
151 ClinicalTrials.gov (NCT03123770) Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients
152 ClinicalTrials.gov (NCT02088515) Nedaplatin (Jiebaishu) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma